Nothing Special   »   [go: up one dir, main page]

AU676525B2 - Substituted dipeptide analogs promote release of growth hormone - Google Patents

Substituted dipeptide analogs promote release of growth hormone

Info

Publication number
AU676525B2
AU676525B2 AU55469/94A AU5546994A AU676525B2 AU 676525 B2 AU676525 B2 AU 676525B2 AU 55469/94 A AU55469/94 A AU 55469/94A AU 5546994 A AU5546994 A AU 5546994A AU 676525 B2 AU676525 B2 AU 676525B2
Authority
AU
Australia
Prior art keywords
amino
methyl
biphenyl
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU55469/94A
Other versions
AU5546994A (en
Inventor
Judith M Pisano
William R Schoen
Matthew J. Wyvratt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU5546994A publication Critical patent/AU5546994A/en
Application granted granted Critical
Publication of AU676525B2 publication Critical patent/AU676525B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

TITLE OF THE INVENTION
SUBSTITUTED DIPEPTIDE ANALOGS PROMOTE RELEASE OF
GROWTH HORMONE
BACKGROUND OF THE INVENTION
Growth hormone, which is secreted from the pituitary, stimulates growth of all tissues of the body that are capable of growing. In addition, growth hormone is known to have the following basic effects on the metabolic process of the body:
1. Increased rate of protein synthesis in all cells of the body;
2. Decreased rate of carbohydrate utilization in cells of the body;
3. Increased mobilization of free fatty acids and use of fatty acids for energy.
A deficiency in growth hormone secretion can result in various medical disorders, such as dwarfism.
Various ways are known to release growth hormone. For example, chemicals such as arginine, L-3,4-dihydroxyphenylalanine (L-DOPA), glucagon, vasopressin, and insulin induced hypoglycemia, as well as activities such as sleep and exercise, indirectly cause growth hormone to be released from the pituitary by acting in some fashion on the hypothalamus perhaps either to decrease somatostatin secretion or to increase the secretion of the known secretagogue growth hormone releasing factor (GRF) or an unknown endogenous growth hormone- releasing hormone or all of these.
In cases where increased levels of growth hormone were desired, the problem was generally solved by providing exogenous growth hormone or by administering an agent which stimulated growth hormone production and/or release. In either case the peptidyl nature of the compound necessitated that it be administered by injection.
Initially the source of growth hormone was the extraction of the pituitary glands of cadavers. This resulted in a very expensive product and carried with it the risk that a disease associated with the source of the pituitary gland could be transmitted to the recipient of the growth hormone. Recently, recombinant growth hormone has become available which, while no longer carrying any risk of disease transmission, is still a very expensive product which must be given by injection or by a nasal spray.
Other compounds have been developed which stimulate the release of endogenous growth hormone such as analogous peptidyl compounds related to GRF or the peptides of U.S. Patent 4,411,890. These peptides, while considerably smaller than growth hormones are still susceptible to various proteases. As with most peptides, their potential for oral bioavailability is low. The instant compounds are highly substituted dipeptide analogs for promoting the release of growth hormone which are stable under various physiological conditions which may be administered parenterally, nasally or by the oral route. SUMMARY OF THE INVENTION
The instant invention covers certain substituted dipeptide analogs which have the ability to stimulate the release of natural or endogenous growth hormone. The compounds thus have the ability to be used to treat conditions which require the stimulation of growth hormone production or secretion such as in humans with a deficiency of natural growth hormone or in animals used for food production where the stimulation of growth hormone will result in a larger, more productive animal. Thus, it is an object of the instant invention to describe the diphenyl substituted dipeptide analogs. It is a further object of this invention to describe procedures for the preparation of such compounds. A still further object is to describe the use of such compounds to increase the secretion of growth hormone in humans and animals. A still further object of this invention is to describe compositions containing the substituted dipeptide analogs for the use of treating humans and animals so as to increase the level of growth hormone secretions. Further objects will become apparent from a reading of the following description. DESCRIPTION OF THE INVENTION
The novel substituted dipeptide analogs of the instant invention are best described in the following structural formula I:
where L is
n is 0 or 1;
p is 0 to 6;
q is 0 to 4;
w is 0 or 1 ;
OH R1 0
I I
X is C=O, O, S(O)m, -CH-, -N-, -CH=CH-;
m is 0 to 2;
R1, R2, R1a, R2a, R1 b, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1 -C3 perfluoroalkyl, C1 -C3 perfluoroalkoxy, -S(O)m- R7a, cyano, nitro, R7bO(CH2)v-, R7bCOO(CH2)v-, R7bOCO-(CH2)v-, R4R5N(CH2)v-, R7bCON(R4)(CH2)v-, R4R5NCO(CH2)v-, R4R5- NCOO(CH2)v-, phenyl or substituted phenyl where the substituenis are from 1 to 3 of halogen, C1 -C6 alkyl, C1 -C6 alkoxy, or hydroxy; R7a and R7b are independently hydrogen, C1 -C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the phenyl substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy and v is 0 to 3;
R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9, or phenoxy substituted with R9;
R9 is
R7bO(CH2)v-, R7bCOO(CH2)v-, R7bOCO(CH2)v-, R7bCO(CH2)v-, R7bO(CH2)vCO-, R4bR12cN(CH2)v-, R12aR12bNCO(CH2)v-,
R12aR12bNCS(CH2)v-, R4bR12aNN(R12b)CO(CH2)v-,
R4bR12aNN(R12b)CS(CH2)v-, R4bR12aNCON(R12c)(CH2)v-,
R4 bR 12aNCSN(R12c)(CH2)v-, R4bR12aNN(R12b)CON(R12c)(CH2)v- ,R4bR 12aNN(R12b)CSN(R12c)(CH2)v-, R4bR12aNN(R12b)- COO(CH2)v-, R4bR12aNCOO(CH2)v-, or R13OCON(R12c)(CH2)v-, where v is 0 to 3; R12a, R12b and R12c are independently R5a, OR5a, or COR5a; R12a and R12b, or R12b and R12c, or R12a and R12c, or R4b and R12a, or R4b and R12a, or R4b and R12c, or R13 and R12c, can be taken together to form -(CH2)r-B-(CH2)s- where B is CHR1 , O, S(O)m or NR10, m is 0, 1 or 2, r and s are independently 0 to 3 and R1 and R10 are as defined;
R13 is C1 -C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are hydroxy, -NR10R1 1 , carboxy, phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy or hydroxy where R10 and R1 1 are as defined; R14 is hydrogen, R1, R2 independently disubstituted phenyl, C1-C10 alkyl or substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, C3- C7 cycloalkyl, R1, R2 independently disubstituted phenyl, C1-C3 alkoxy, R1, R2 independently disubstituted phenyl C1-C5 alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl or -NR10R1 1 where R1 , R2, R10 and R1 1 are as defined; R15 is hydrogen, trifluoromethyl, R1 , R2 independently disubstituted phenyl, R1, R2 independently disubstituted naphthyl, C3-C7 cycloalkyl, C1-C10 alkyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, C3-C7 cycloalkyl, R1, R2 independently disubstituted phenyl, R1, R2 independently disubstituted phenyl C1-C3 alkoxy, R1, R2 independently disubstituted naphthyl, R1 , R2 independently disubstituted naphthyl C1-C3 alkoxy, C1-C5 alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl,
-NR1 0R1 1 or R1, R2 independently disubstituted heterocycle, where the heterocycle is imidazole, thiophene, furan, pyrrole, oxazole, thiazole, triazole, tetrazole, pyridine, benzofuran, benzothiophene, benzimi- dazole, indole, 7-azaindole, oxindole or indazole; where R1, R2, R10 and R1 1 are as defined above;
R4, R4a, R4b, R5 and R5a are independently hydrogen, phenyl, substituted phenyl, C1-C10 alkyl, substituted C1-C10 alkyl, C3-C10 alkenyl, substituted C3-C10 alkenyl, C3-C10 alkynyl, or substituted C3- C10 alkynyl where the substituents on the phenyl, alkyl, alkenyl or alkynyl are from 1 to 5 of hydroxy, C1-C6 alkoxy, C3-C7 cycloalkyl, fluoro, R1 , R2 independently disubstituted phenyl C1-C3 alkoxy, R1, R2 independently disubstituted phenyl, C1-C20-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, or -NR10R1 1 where R10 and R1 1 are independently hydrogen, C1-C6 alkyl, phenyl, phenyl C1-C6 alkyl, C1-C5-alkoxycarbonyl, C1-C5-alkanoyl or C1-C6 alkyl; or R4 and R5 can be taken together to form -(CH2)rB(CH2)s- where B, r, s, R1 and R10 are as defined above;
R6 is hydrogen, C1-C10 alkyl, phenyl or phenyl C1-C10 alkyl;
A is
where x and y are independently 0-3; R8 and R8a are independently hydrogen, C1-C10 alkyl, trifluoromethyl, phenyl, substituted C1 -C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, C3- C7 cycloalkyl, R1, R2 independently disubstituted phenyl C1-C3 alkoxy, R1, R2 independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, or -NR10R1 1 where R10 and R1 1 are as defined above; or R8 and R8a can be taken together to form -(CH2)t- where t is 2 to 6; and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof.
In the above structural formula and throughout the instant specification, the following terms have the indicated meanings:
The alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration. Exemplary of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, and the like.
The alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a straight or branched configuration. Exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.
The term "halogen" is intended to include the halogen atom fluorine, chlorine, bromine and iodine.
Certain of the above defined terms may occur more than once in the above formula and upon such occurrence each term shall be defined independently of the other.
Preferred compounds of the instant invention are realized when in the above structural formula: n is 0 or 1;
p is 0 to 4;
q is 0 to 2;
w is 0 or 1 ; R1 0
|
X is O, S(O)m, -N-, -CH=CH-;
m is 0 to 2; R1, R2, R1 a, R2a, R1b, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, -S(O)mR7a, R7bO(CH2)v-,
R7bCOO(CH2)v-, R7bOCO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; R7a and R7b are independently hydrogen, C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl; phenyl and v is 0 to 2;
R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9, or phenoxy substituted with R9; R9 is as defined above; R12a, R12b and R12c are independently R5a, OR5a, or COR5a; R12a and R12b, or R12b and R12c, or R13 and R12b or R12a and R4b can be taken together to form -(CH2)r-B-(CH2)s- where B is CHR1, O, S(O)m or NR10, m is 0, 1 or 2, r and s are independently 0 to 3, R1 is as defined above and R10 is hydrogen, C1-C6 alkyl, phenyl C1-C6 alkyl or C1-C5 alkanoyl-C1-C6 alkyl; R13 is C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are hydroxy, NR10R1 1 , carboxy, phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy or hydroxy; R14 and R15 are as defined above; R4, R4a, R4b, R5 and R5a are independently hydrogen, phenyl, substituted phenyl, C1-C10 alkyl, substituted C1-C10 alkyl, where the substituents on the alkyl or phenyl are from 1 to 5 of hydroxy, C1-C6 alkoxy, C3-C7 cycloalkyl, fluoro, R1 substituted or R1, R2 independently disubstituted phenyl C1-C3 alkoxy, R1 substituted or R1, R2 independently disubstituted phenyl, C1-C20-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy or formyl; R4 and R5 can be taken together to form -(CH2)rB(CH2)s- where B is CHR1, O, S(O)m or N-R10, r and s are independently 1 to 3 and R1 and R10 are as defined above;
R6 is hydrogen, C1-C10 alkyl or phenyl C1-C10 alkyl; A is
where x and y are independently 0-2; R8, R8a and R8b are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, R1 , R2
independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, -NR10R1 1 where R10 and RH are independently hydrogen, C1-C6 alkyl, or C1-C5 alkanoyl-C1-C6 alkyl; or R8 and R8a can be taken together to form -(CH2)t- where t is 2 to 4; and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof.
Additional preferred compounds are realized in the above structural formula when:
n is 0 or 1;
p is 0 to 3;
q is 0 to 2;
w is 0 or 1 ;
X is O, S(O)m or -CH=CH-;
m is 0 or 1; R1, R2, R1 a, R2a, R1b, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, -S(O)mR7a, R7bO(CH2)v-,
R7bCOO(CH2)v-, R7bOCO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1 -C6 alkyl, C1-C6 alkoxy, or hydroxy; R7a and R7b are independently hydrogen, C1-C6 alkyl, substituted C1 - C6 alkyl, where the substituents are phenyl and v is 0 to 2;
R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9, or phenoxy substituted with R9;
R9 is as defined above; R12a, R12b and R12c are independently R5a or OR5a. R12a and R12b, or R12b and R12c, or R13 and R12b or R12a and R4b can be taken together to form -(CH2)r-B-(CH2)s- where B is CHR1, O, S(O)m or NR10, m is 0, 1 or 2, r and s are independently 0 to 2, R1 is as defined above and R10 is hydrogen, C1-C6 alkyl or C1-C5 alkanoyl-C1-C6 alkyl; R13 is C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1- C6 alkoxy or hydroxy; R14 and R15 are as defined above; R4, R4a, R4b, R5 and R5a are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl, where the substituents on the alkyl are from 1 to 5 of hydroxy, C1-C6 alkoxy, fluoro, R1 substituted or R1, R2 independently disubstituted phenyl, C1-C20-alkanoyloxy, C1-C5 alkoxycarbonyl or carboxy;
R6 is hydrogen or C1-C10 alkyl; A is
where x and y are independently 0-2; R8, R8a and R8b are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, R1 substituted or R1, R2 independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy; or R8 and R8a can be taken together to form -(CH2)t- where t is 2; or R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof. Still further preferred compounds of the instant invention are realized in the above structural formula when;
n is 0 or 1;
p is 0 to 2;
q is 1 ;
w is 1;
X is O, S(O)m;
m is 0 or 1; R1 , R2, R1 a, R2a, R1b, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C 1 -C3 perfluoroalkyl, -S(O)mR7a, R7bO(CH2)v-, R7bCOO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1 -C6 alkoxy, or hydroxy; R7a and R7b are independently hydrogen, C1-C6 alkyl, substituted C1- C6 alkyl, where the substituents are phenyl and v is 0 or 1 ; R3a and R3b are independently hydrogen, R9, or C1-C6 alkyl substituted with R9;
R9 is as defined above; R12a, R12b and R12c are independently R5a. R 12a and R12b, or R 12b and R12c, or R13 and R12b or R12a and R4b can be taken together to form -(CH2)r-B-(CH2)s- where B is CHR1, O, S(O)m or NR10, m is 0, 1 or 2, r and s are independently 0 to 2, R1 is as defined above and R10 is hydrogen, C1-C6 alkyl or C1-C5 alkanoyl C1-C6 alkyl; R13 is C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1- C6 alkoxy or hydroxy; R14 and R15 are as defined above; R4, R4a, R4b, R5 and R5a are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl, where the substituents on the alkyl are from 1 to 3 of hydroxy, C1-C3 alkoxy, fluoro, R1 substituted or R1, R2 independently disubstituted phenyl, C1-C20 alkanoyloxy, C1-C5 alkoxycarbonyl or carboxy;
R6 is hydrogen;
A is
where x and y are independently 0-1; R8, R8a and R8b are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, R1 substituted or R1, R2 independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy; or R8 and R8a can be taken together to form -(CH2)t- where t is 2; and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the teiminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof.
Representative preferred growth hormone releasing compounds of the present invention include the following:
1. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1 ,1' -biphenyl]-4-yl]methyl]-benzene- butanamide
2. (R)-α-[(2-Amino-2-methyl-1-oxoproρyl)amino]-N-[[2'- (1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]benzene- butanamide
3. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]benzenebutanamide
4. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]benzenebutanamide
5. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2,-(1H- tetrazol-5-yl)[1 ,1'-biphenyl]-4-yl]methyl]-benzenepentana- mide 6. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- (1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]benzene- pentanamide
7. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]benzenepentanamide
8. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]benzenepentanamide
9. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-indole-3- propanamide
10. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-
(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]-1H-indole- 3-propanamide
1 1. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide
12. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1 '-biphenyl]-4- yl]methyl]- 1 H-indole-3-propanamide
13. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1 '-biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]propanamide 14. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- (1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]-3-[(phenylmethyl)oxy]propanamide 15. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)oxy]-propanamide 16. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)oxy]-propanamide 17. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]-3-[[(2,6- difluorophenyl)methyl]oxy]-propanamide 18. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- (1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]-3-[[(2,6- difluorophenyl)methyl]oxy]-propanamide 19. (R)-α-[[3-[2(R)-Hydroxyproρyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluorophenyl)-methyl]oxy]pro- panamide 20. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluorophenyl)-methyl]oxy]- propanamide 21. (R)-4'-[[[2-[(3-Amino-3-methyl-1-oxobutyl)amino]-1-oxo- 4-phenylbutyl]amino]methyl]-N-ethyl[1 ,1'-biphenyl]-2- carboxamide 22. (R)-4'-[[[2-[(2-Amino-2-methyl-1-oxopropyl)-amino]-1- oxo-4-phenylbutyl]amino]methyl]-N-ethyl[1,1'-biphenyl]-2- carboxamide
23. (R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-4-phenylbutyl]-amino]methyl]-N- ethyl[1,1'-biphenyl]-2-carboxamide
24. (R)-4'-[[[2-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-4-phenylbutyl]-amino]methyl]-N- ethyl[1,1'-biphenyl]-2-carboxamide
25. (R)-4'-[[[2-[(3-Amino-3-methyl-1-oxobutyl)amino]-1-oxo- 5-phenylpentyl]amino]methyl]-N-ethyl[1,1'-biphenyl]-2- carboxamide 26. (R)-4'-[[[2-[(2-Amino-2-methyl-1-oxopropyl)-amino]-1- oxo-5-phenylpentyl]amino]methyl]-N-ethyl[1,1'-biphenyl]- 2-carboxamide
27. (R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-1-oxo-5-phenylpentyl]-amino]methyl]-N- ethyl[1,1'-biphenyl]-2-carboxamide 28. (R)-4'-[[[2-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-5-phenylpentyl]-amino]methyl]-N- ethyl[1,1'-biphenyl]-2-carboxamide
29. (R)-4'-[[[2-[(3-Amino-3-methyl-1-oxobutyl)amino]-1-oxo- 3-(1H-indole-3-yl)propyl]amino]methyl]-N-ethyl[1,1'- biphenyl]-2-carboxamide 30. (R)-4'-[[[2-[(2-Amino-2-methyl-1-oxopropyl)-amino]-1- oxo-3-(1H-indole-3-yl)propyl]amino]-methyl]-N-ethyl[1,1 '- biphenyl]-2-carboxamide
31. (R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-3-(1H-indole-3-yl)propyl]amino]- methyl]-N-ethyl[1 ,1'-biphenyl]-2-carboxamide
32. (R)-4'-[[[2-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-3-(1H-indole-3-yl)propyl]- amino]methyl]-N-ethyl[1,1'-biphenyl]-2-carboxamide
33. (R)-4'-[[[2-[(3-Amino-3-methyl-1-oxobutyl)amino]-1-oxo- 3-[(phenylmemyl)oxy]propyl]amino]methyl]-N-ethyl[1,1'- biphenyl]-2-carboxamide
34. (R)-4'-[[[2-[(2-Amino-2-methyl-1-oxopropyl)-amino]-1- oxo-3-[(phenylmethyl)oxy]propyl]amino]-methyl]-N- ethyl[1,1'-biphenyl]-2-carboxamide
35. (R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-3-[(phenylmethyl)-oxy]propyl]- aminojmethyl]-N-ethyl[1,1'-biphenyl]-2-carboxamide 36. (R)-4'-[[[2-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-3-[(phenylmethyl)-oxy]propyl]- amino]methyl]-N-ethyl[1,1'-biphenyl]-2-carboxamide
37. (R)-4'-[[[2-[(3-Amino-3-methyl-1-oxobutyl)amino]-1-oxo- 3-[[(2,6-difluorophenyl)methyl]oxy]propyl]-amino]methyl]- N-ethyl[1,1 '-biphenyl]-2-carboxamide 38. (R)-4'-[[[2-[(2-Amino-2-methyl-1-oxopropyl)-amino]-1- oxo-3-[[(2,6-difluorophenyl)methyl]oxy]-propyl]amino]- methyl]-N-ethyl[1,1'-biphenyl]-2-carboxamide 39. (R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-1-oxo-3-[[(2,6-difluoro-phenyl)methyl]- oxy]propyl]amino]methyl]-N-ethyl-[1,1'-biphenyl]-2- carboxamide 40. (R)-4'-[[[2-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-3-[[(2,6-difluoro-phenyl)methyl]- oxy]propyl]amino]methyl]-N-ethyl-[1 ,1 '-biphenyl]-2- carboxamide 41. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-
[[(methylamino)carbonyl]amino][1,1'-biphenyl]-4- yl]methyl]benzenebutanamide
42. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[(methylamino)carbonyl]amino][1,1'-biphenyl]-4- yl]methyl]benzenebutanamide
43. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]- amino][1,1'-biphenyl]-4-yl]methyl]benzenebutanamide
44. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]- amino][1,1 '-biphenyl]-4-yl]methyl]benzenebutanamide
45. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'- [[(methylamino)carbonyl]amino][1,1'-biphenyl]-4- yl]methyl]benzenepentanamide 46. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[(methylamino)carbonyl]amino][1,1'-biphenyl]-4- yl]methyl]benzenepentanamide
47. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]- amino][1,1'-biphenyl]-4-yl]methyl]benzenepentanamide
48. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]- amino][1,1'-biphenyl]-4-yl]methyl]benzenepentanamide
49. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'- [[(methylamino)carbonyl]amino][1,1'-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide
50. (R)-α-[(2-Amino-2-methyl-1-oxoproρyl)amino]-N-[[2'- [[(methylamino)carbonyl]amino][1,1'-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide
51. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]- amino][1,1'-biphenyl]-4-yl]methyl]-1H-indole-3- propanamide
52. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]- amino][1 ,1'-biphenyl]-4-yl]methyl]-1H-indole-3- propanamide
53. (R)-α-[(3-Amino-3-methyl-1 -oxobutyl)amino]-N-[[2'- [[(methylamino)carbonyl]amino][1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)oxy]-propanamide 54. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[(methylamino)carbonyl]amino][1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)oxy]-propanamide 55. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]-amino]- [1,1'-biphenyl]-4-yl]methyl]-3-[(phenyl¬methyl)oxy]propa- namide 56. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]- amino][1,1'-biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]propanamide 57. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'- [[(methylamino)carbonyl]amino][1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluorophenyl)-methyl]oxy]- propanamide 58. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[(methylamino)carbonyl]amino][1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluorophenyl)-methyl]oxy]- propanamide 59. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]- amino][1,1'-biphenyl]-4-yl]methyl]-3-[[(2,6- difluorophenyl)methyl]oxy]propanamide
60. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]-amino]- [1,1'-biphenyl]-4-yl]methyl]-3-[[(2,6-difluorophenyl)- methyl]oxy]propanamide 61. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'- hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-benzene- butanamide
62. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-benzene- butanamide
63. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4- yl]methyl]benzenebutanamide
64. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4- yl]methyl]benzenebutanamide
65. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'- hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-benzene- pentanamide
66. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-benzene- pentanamide
67. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4- yl]methyl]benzenepentanamide
68. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-hydroxymethyl[1 ,1 '-biphenyl]-4- yl]methyl]benzenepentanamide 69. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'- hydroxymethyl[1 ,1 '-biphenyl]-4-yl]methyl]-1H-indole-3- propanamide
70. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- hydroxymethyl[1 ,1'-biphenyl]-4-yl]methyl]-1H-indole-3- propanamide
71. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-hydroxymethyl[1,1 '-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide
72. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-hydroxymethyl[1,1 '-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide
73. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'- hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]propanamide
74. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- hy droxymethyl[1,1'-biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]propanamide 75. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)oxy]propanamide
76. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-N-[[2'-hydroxymethyl[1,1 '-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)oxy]propanamide 77. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'- hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-3-[[(2,6- difluorophenyl)methyl]oxy]propanamide
78. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- hydroxymeιhyl[1,1'-biphenyl]-4-yl]methyl]-3-[[(2,6- difluorophenyl)methyl]oxy]propanamide
79. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluorophenyl)-methyl]oxy]- propanamide
80. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluorophenyl)-methyl]oxy]- propanamide
81. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'- [[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]benzenebutanamide
82. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]benzenebutanamide
83. (R)-α-[[3-[2(R)-Hydroxyproρyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[[(methylamino)carbonyl]- amino]methyl][1,1'-biphenyl]-4-yl]methyl]benzene- butanamide 84. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[[(methylamino)carbon-yl]- amino]methyl][1,1'-biphenyl]-4-yl]methyl]-benzene- butanamide
85. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'- [[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]benzenepentanamide
86. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[[(methylamino)carbonyl]amino]memyl]-[1,1'-biphenyl]-4- yl]methyl]benzenepentanamide
87. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[[(methylamino)carbonyl]- amino]methyl][1,1'-biphenyl]-4-yl]methyl]benzene- pentanamide
88. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[[(methylamino)carbon- yl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]ben- zenepentanamide
89. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-
[[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide
90. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-
[[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide 91. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2-[[[(methylamino)carbonyl]- amino]methyl][1,1'-biphenyl]-4-yl]methyl]-1H-indole-3- propanamide
92. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[[(methylamino)carbon-yl]amino]- methyl][1,1'-biphenyl]-4-yl]methyl]-1H-indole-3- propanamide
93. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-
[[[(methylamino)carbonyl]aminojmethyl]-[1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)-oxy]propanamide 94. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-
[[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)-oxy]propanamide
95. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[[(methylamino)carbonyl]- amino]methyl][1,1'-biphenyl]-4-yl]methyl]-3- [(phenylmethyl)oxy]propanamide
96. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-N-[[2'-[[[(methylamino)carbon-yl]- amino]methyl][1,1'-biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]propanamide
97. (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-
[[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluoro-phenyl)-methyl]oxy]propana- mide 98. (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluoro-phenyl)methyl]oxy]- propanamide
99. (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[[(methylamino)carbonyl]- amino]methyl][1,1'-biphenyl]-4-yl]methyl]-3-[[(2,6- difluorophenyl)methyl]oxy]propanamide
100. (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[[(methylamino)carbon- yl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-3-[[(2,6- difluorophenyl)methyl]oxy]propanamide
Representative examples of the nomenclature employed are given below:
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H-tetrazol-5- yl)[1,1' -biphenyl]-4-yl]methyl]benzenepropanamide
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-[[(methyl- amino)carbonyl]amino][1,1'-biphenyl]-4-yl]-methyl]-1H-imidazole-4-yl- propanamide
(R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-1-oxo-3-(1H-indole-3-yl)propyl]amino]-methyl]-N-methyl[1 ,1 '- biphenyl]-2-carboxamide
(S)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]amino]- N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-3-[(phenylmethyl)- thio]propanamide
The compounds of the instant invention all have at least one asymmetric center as noted by the asterisk in the structural Formula I above. Additional asymmetric centers may be present on the molecule depending upon the nature of the various substituents on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof, be included within the ambit of the instant invention. In the case of the asymmetric center represented by the asterisk in Formula I, it has been found that the compound in which the 3-amino substituent is above the plane of the structure, as seen in Formula la, is more active and thus more prefened over the compound in which the 3-amino substituent is below the plane of the structure. This center will be designated according to the R/S rules as either R or S depending upon the values of X, n, p and R15.
The instant compounds are generally isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids. Examples of such acids are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic and the like. In addition, certain compounds containing an acidic function such as a carboxy can be isolated in the form of their inorganic salt in which the counterion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.
Compounds I of the present invention are prepared from amino acid intermediates II as described in the following reaction schemes.
Amino acid intermediates 1 are, in some cases, commercially available in the form of their N-t-butoxycarbonyl or N- benzyloxycarbonyl derivatives. These intermediates can also be prepared by a variety of methods described in the literature and familiar to one skilled in the art. For example, the Strecker synthesis may be employed for the construction of racemic amino acid intermediates. Resolution can be achieved by classical methods, for example separation of diastereomeric salts by fractional crystallization. Alternatively, a chiral amino acid synthesis may be employed using the procedures described by R.M. Williams and M.N. Im (J. Amer. Chem. Soc. , 1 13, 9276-9286, 1991.). Conversion of the free amino acid product to its N-t-butoxycarbonyl (BOC) derivative can be achieved by a number of methods known in the art, for example, treatment with di- t-butyl dicarbonate in an inert solvent such as methylene chloride.
Benzyloxycarbonyl (CBz) protected derivatives are obtained by treatment of the amino acid with, for example, benzyl chloroformate.
SCHEME 1
As shown in Scheme 1, formation of the benzyl ester 2 is carried out by treatment with benzyl alcohol in the presence of a coupling agent, such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), in methylene chloride with a catalytic amount of 4-dimethylaminopyridine. Removal of the BOC protecting group through the use of trifluoroacetic acid in methylene chloride or hydrochloric acid in tetrahydrofuran gives the amine salt 3. Reductive alkylation with an aldehyde and a mild reducing agent, such as sodium cyanoborohydride, leads to the desired intermediate II.
Attachment of the amino acid sidechain to intermediates of formula II is accomplished by the route shown in Scheme 2. Coupling is conveniently carried out by the use of an appropriately protected amino acid derivative, such as that illustrated by formula III, and a coupling reagent such as benzotriazol-1-yloxytris(dimethylamino)- phosphonium hexafluorophosphate ("BOP") in an inert solvent such as methylene chloride. Separation of unwanted side products, and purification of intermediates is achieved by chromatography on silica gel, employing flash chromatography (W.C. Still, M. Kahn and A.
Mitra, J. Org. Chem., 43, 2923 (1978)) or by medium pressure liquid chromatography. Removal of the benzyl ester by hydrogenolysis or by saponification in the presence of a strong base, such as sodium
hydroxide, affords the product IV. It may be appreciated by one skilled in the art that the protecting group G must be selected to be compatible with the conditions employed for removal of the specific class of ester present in 4. Hence, as illustrated for the benzyl ester 4, G is taken as t- butoxycarbonyl. It may further be appreciated that other combinations of protecting group G and ester functionality may be employed; for example, the benzyloxycarbonyl protecting group is inert to the standard conditions of aqueous sodium hydroxide employed to
hydrolyze methyl or ethyl esters. SCHEME 2
The protected amino acid derivatives III are, in many cases, commercially available in t-butoxycarbonyl (BOC) or benzyloxy- carbonyl (CBz) forms. A useful method to prepare the prefened sidechain 9 is shown in Scheme 3. SCHEME 3
Reaction of isobutylene with N-chlorosulfonyl-isocyanate 5 in diethyl ether gives the azetidinone derivative 6. Removal of the chlorosulfonyl group with aqueous sodium sulfite followed by reaction with di-t-butyl-dicarbonate gives the BOC-protected intermediate 8. Alkaline hydrolysis gives the protected amino acid derivative 9 in good overall yield.
Attachment of the substituted phenyl sidechain V is achieved as shown in Scheme 4. Using the aforementioned BOP reagent, coupling is conveniently carried out in an inert solvent, such as methylene chloride, to give compounds of formula VII in protected form. SCHEME 4
G is t-butoxycarbonyl or benzyloxycarbonyl
The substituted phenyl sidechains V are prepared from the conesponding alkylating agent VI by displacement of the leaving group Y with sodium azide as shown in Scheme 5. Reduction of the azide product by hydrogenation in the presence of a transition metal catalyst, or alternatively by reaction with triphenylphosphine followed by hydrolysis, gives the desired amine derivative 10. Conversion to the desired intermediate V is achieved by the aforementioned reductive alkylation procedure. SCHEME 5
Y is a leaving group
As illustratrated in Scheme 6 an alternative route involves coupling of intermediate IV with R14NH2 using one of the coupling reagents described previously, followed by alkylation of the amide bond with VI. Alkylation is carried out in an inert solvent, such as
dimethylformamide, using a strong base such as sodium hydride or potassium t-butoxide at temperatures of 0°-100°C. Alkylating agents VI are, in some cases, commercially available or may be prepared by the procedures described in the following schemes. SCHEME 6
G is t-butoxycarbonyl or benzyloxycarbonyl
Alkylating agents VI are, in some cases commercially available compounds or may be prepared by methods described in the literature and familiar to one skilled in the art. Compounds of formula I wherein R3a or R3b is a tetrazole (13) are prepared as described in Scheme 7 by reaction of IV with a suitably substituted intermediate 11 containing a nitrile as tetrazole precursor. Elaboration to the desired product 13 is carried out by treatment with trimethyltin azide in boiling toluene.
SCHEME 7
H
SCHEME 7 (cont'd)
G=t-butoxycarbonyl or benzyloxycarbonyl A useful method to prepare the prefened intermediate 18 is shown in Scheme 8, and in U.S. Patent 5,039,814.
SCHEME 8
SCHEME 8 (cont'd)
As outlined in Scheme 8, benzonitrile is treated with sodium azide and zinc chloride to give 5-phenyltetrazole 14 which is converted to the N-trityl derivative 15 by treatment with triphenyl- methyl chloride and triethylamine. The zinc reagent 16 was prepared by treatment with n-butyl lithium followed by zinc chloride. Coupling with 4-iodotoluene using the catalyst bis(triphenylphosphine)nickel(II) dichloride gives the biphenyl product 17 in high yield. Reaction with N-bromosuccinimide and AIBN gives bromide 18. Conversion to the requisite amine derivative V is achieved by the procedure described in Scheme 5.
Compounds of Formula I wherein R3a or R3b are taken as R4R5NCO can be prepared by several methods. For example, as shown in Scheme 9, compound 20 wherein R4 and R5 are both hydrogen is conveniently prepared by hydrolysis of a nitrile precursor 19. SCHEME 9
Thus, treatment of the nitrile 19 with hydrogen peroxide and a strong base, such as potassium carbonate, in a polar solvent, such as dimethylsulfoxide at temperatures of 25°C to 150°C results in formation of the amide derivative 20.
A useful method of preparing the intermediate 23 is outlined in Scheme 10. SCHEME 10
Thus, treatment of 4-(methylphenyl)trimethyl stannane 21 with 2-bromobenzonitrile in dimethylformamide at 100°C in the presence of bis-triphenylphosphine palladium (II) chloride results in coupling to form the biphenyl nitrile 22 in high yield. Conversion to bromide 23 is achieved by treatment with N-bromosuccinimide and a radical initiator, such as azobisisobutyronitrile (AIBN), in refluxing carbon tetrachloride. Conversion to the requisite amine derivative V is achieved by the procedure described in Scheme 5.
Compounds of Formula I wherein R3a or R3b are taken as R4R5NCO and R4 and/or R5 are other than hydrogen are prepared from the conesponding carboxylic acid derivatives 24 as shown in Scheme 11. SCHEME 11
Coupling of the carboxylic acid derivative 24 with R4R5NH is conveniently carried out by the use of a coupling reagent such as benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate ("BOP") in an inert solvent such as methylene chloride. The requisite carboxylic acid precursors can be prepared as illustrated in Scheme 12 for the biphenyl compound 24.
A convenient method to prepare the useful intermediate 30 is shown in Scheme 13. Metallation of 4-iodotoluene with t-butyl- lithium in tetrahydro-furan, followed by treatment with zinc chloride gives the intermediate zinc reagent 28. Coupling of 28 with t-butyl 2- bromobenzoate in the presence of bis(triρhenylphosphine)nickel(II) chloride affords the biphenyl product 29 in high yield. Bromination to give the desired intermediate 30 is carried out under the aforementioned conditions. Conversion to the requisite amine derivative V is achieved by the procedure described in Scheme 5.
SCHEME 13
Compounds of formula I where R3a or R3b is a carbamate, semicarbazide or urea derivative, wherein this functionality is attached to the phenyl ring by a nitrogen atom are prepared from intermediate 32, obtained by reaction with a derivative 31 wherein R3a or R3b is a nitro group as shown in Scheme 14. SCHEME 14
A useful method of synthesizing a prefened intermediate shown in reaction Scheme 15. SCHEME 15
Reaction of 4-tolylboronic acid 33 with 2-bromo- nitrobenzene 34 in the presence of a transition metal catalyst such as (tetrakis)triphenylphosphine palladium (O) in a mixed solvent system containing aqueous sodium hydroxide, water, 2-propanol and benzene at elevated temperatures for several hours gives the coupled product 35 in good overall yield. Chromatographic purification and separation of unwanted by-products is conveniently performed on silica, eluting with common organic solvents such as hexane, ethyl acetate and methylene chloride. Conversion of 35 to the bromide derivative 36 is
accomplished by treatment with N-bromosuccinimide in refluxing carbon tetrachloride in the presence of a radical initiator such as benzoyl peroxide or 2,2-azobisisobutyronitrile (AIBN). Conversion to the requisite amine derivative V is acheived by the procedure described in Scheme 5.
As shown in Scheme 16, reduction of the nitro group of 32 is achieved by hydrogenation in the presence of a metal catalyst, such as palladium on carbon, in a protic solvent such as methanol or ethanol. It may be appreciated by one skilled in the art that for certain compounds where catalytic hydrogenation is incompatible with existing
functionality, alternative methods of reduction are indicated, such as chemical reduction with stannous chloride under acidic conditions. It should also be noted that the protecting group G in intermediate 32 must be compatible with the experimental conditions anticipated for reduction. For example, intermediate 32 wherein G is t-butoxycarbonyl (BOC) are stable to the conditions of catalytic reduction employed in the conversion to 37. Intermediate 37 may also be further elaborated to new intermediate 38 by reductive alkylation with an aldehyde by the aforementioned procedures.
SCHEME 16 (cont'd)
Elaboration of 37 to carbamate compounds is achieved by reaction with the appropriate chloroformate reagent in pyridine or in methylene chloride with triethylamine as shown in Scheme 17. SCHEME 17
R
Transformation of amine intermediate 32 to urea derivatives is accomplished in several ways. Terminally disubstituted compounds 40 can be obtained directly by reaction of 37 with a disubstituted carbamoyl chloride in an inert solvent such as methylene chloride in the presence of triethylamine or 4-dimethylaminopyridine. In addition, monosubstituted compounds 41 wherein either R4b or R 12a is hydrogen are obtained from 37 by reaction with an isocyanate as shown in Scheme 18.
SCHEME 18
SCHEME 18 (cont'd)
Alternatively, amine 32 is converted to an isocyanate 42 by treatment with phosgene or an equivalent reagent such as bis(trichloro- methyl)carbonate (triphosgene) as indicated in Scheme 19. Subsequent reaction of 42 with primary or secondary amines in an inert solvent such as methylene chloride gives the corresponding urea derivates 43 in good yield. Isocyanate 42 is also converted to substituted semi- carbazides 44 or hydroxy- or alkoxyureas 45 by reaction with substituted hydrazines or hydroxy- or alkoxy lamines, respectively.
SCHEME 19
SCHEME 19 (cont'd)
Compounds of formula I where R3a or R3b is a carbazate or carbamate derivative where attachment to the phenyl ring is through the oxygen atom of the carbazate or carbamate linkage are prepared from acetophenone intermediates 46 as indicated in Scheme 20. SCHEME 20 (cont'd)
2 a
b
Oxidative rearrangement of 46 through the use of a peroxy-carboxylic acid (Baeyer-Villager reaction) such as m- chloroperbenzoic acid gives the ester 47 which is hydrolyzed in the presence of a strong base such as sodium or lithium hydroxide to give phenol 48. Reaction of 48 with an isocyanate leads directly to
carbamate analogs 49. Additionally, treatment of 48 with N,N'- carbonyldiimidazole in dimethylformamide can form an activated intermediate which will react with substituted hydrazine reagents to give carbazate products 50.
Compounds of formula I wherein R3a or R3b contains the linkage -CH2N(R12b)- can be prepared from the t-butyl ester intermediate 51 as described in Scheme 21. Removal of the t-butyl ester through the use of trifluoroacetic acid gives the carboxylic acid 24. It may be appreciated by one skilled in the art that the protecting group G in 51 must therefore be compatible with the strongly acidic conditions employed for ester cleavage, hence G is taken as benzyloxycarbonyl. Conversion of the carboxylic acid to the benzylamine derivative 52 can be achieved by a five-step sequence consisting of: 1) formation of a mixed anhydride with isobutyl chloroformate; 2) reduction with sodium borohydride to the benzyl alcohol; 3) formation of the mesylate with methanesulfonyl chloride; 4) formation of the azide by reaction with sodium azide, and finally, 5) reduction of the azide with tin(II) chloride. The benzylamine intermediate 52 can be further elaborated to 53 by the aforementioned reductive amination procedure.
SCHEME 21 (Cont'd)
O
II
1. iBu-O-C-CI, N-methyl- morpholine
2. sodium borohydride
24 --------------------------------→
3. CH3SO2CI
4. sodium azide
5. SnCI2, aqueous dioxane
52 G is benzyloxycarbonyl
SCHEME21 (Cont'd)
53 G is benzyloxycarbonyl Reaction of amine 53 with the appropriate reagents to form urea-linked compounds 54 and 55 carbamate-linked compounds 56, and amide-linked structures 57 are illustrated in Scheme 22.
A useful preparation of the protected benzylamine intermediate 62 is shown in Scheme 23. Metallation of 4-bromobenzyl t-butyldimethylsilylether 58 with n-butyllithium followed by treatment with trimethyl borate gives the aryl boronic acid 59. Reaction of 59 with 2-bromo-N-(t-butoxycarbonyl)benzylamine 60 in the presence of tetrakis(triphenylphosphine)palladium(0) and barium hydroxide in aqueous 1,2-dimethoxyethane at elevated temperature gives the coupled product 61 in good yield. Desilylation is carried out by treatment with tetra-n-butylammonium fluoride; conversion to the O-methanesulfonate 62 is achieved by reaction of the intermediate benzyl alcohol with methanesulfonic anhydride. Conversion to the requisite amine derivative V is achieved by the procedure described in Scheme 5.
SCHEME 23
Conversion to the final products of formula I wherein R5 is hydrogen, is carried out by simultaneous or sequential removal of all protecting groups from intermediate VII as illustrated in Scheme 24. Removal of benzyloxycarbonyl groups can be achieved by a number of methods known in the art; for example, catalytic hydrogenation with hydrogen in the presence of a platinum or palladium catalyst in a protic solvent such as methanol. In cases where catalytic hydrogenation is contraindicated by the presence of other potentially reactive
functionality, removal of benzyloxycarbonyl groups can also be achieved by treatment with a solution of hydrogen bromide in acetic acid. Catalytic hydrogenation is also employed in the removal of N- triphenylmethyl (trityl) protecting groups. Removal of t-butoxycarbonyl (BOC) protecting groups is carried out by treatment of a solution in a solvent such as methylene chloride or methanol, with a strong acid, such as hydrochloric acid or trifluoroacetic acid.
Conditions required to remove other protecting groups which may be present can be found in Protective Groups in Organic Synthesis.
SCHEME 24
Compounds of formula I wherein R4 and R5 are each hydrogen can be further elaborated by reductive alkylation with an aldehyde by the aforementioned procedures or by alkylations such as by reaction with various epoxides as shown in Scheme 25. The products, obtained as hydrochloride or trifluoroacetate salts, are conveniently purified by reverse phase high performance liquid chromatography (HPLC) or by recrystallization.
SCHEME 25
It is noted that the order of carrying out the foregoing reaction schemes is not significant and it is within the skill of one skilled in the art to vary the order of reactions to facilitate the reaction or to avoid unwanted reaction products. The growth hormone releasing compounds of Formula I are useful in vitro as unique tools for understanding how growth hormone secretion is regulated at the pituitary level. This includes use in the evaluation of many factors thought or known to influence growth hormone secretion such as age, sex, nutritional factors, glucose, amino acids, fatty acids, as well as fasting and non-fasting states. In addition, the compounds of this invention can be used in the evaluation of how other hormones modify growth hormone releasing activity. For example, it has already been established that somatostatin inhibits growth hormone release. Other hormones that are important and in need of study as to their effect on growth hormone release include the gonadal hormones, e.g., testosterone, estradiol, and progesterone; the adrenal hormones, e.g., cortisol and other corticoids, pinephrine and norepinephrine; the pancreatic and gastrointestinal hormones, e.g., insulin, glucagon, gastrin, secretin; the vasoactive intestinal peptides, e.g., bombesin; and the thyroid hormones, e.g., thyroxine and
triiodothyronine. The compounds of Formula I can also be employed to investigate the possible negative or positive feedback effects of some of the pituitary hormones, e.g., growth hormone and endorphin peptides, on the pituitary to modify growth hormone release. Of particular scientific importance is the use of these compounds to elucidate the subcellular mechanisms mediating the release of growth hormone.
The compounds of Formula I can be administered to animals, including man, to release growth hormone in vivo. For example, the compounds can be administered to commercially important animals such as swine, cattle, sheep and the like to accelerate and increase their rate and extent of growth, and to increase milk production in such animals. In addition, these compounds can be administered to humans in vivo as a diagnostic tool to directly determine whether the pituitary is capable of releasing growth hormone. For example, the compounds of Formula I can be administered in vivo to children.
Serum samples taken before and after such administration can be assayed for growth hormone. Comparison of the amounts of growth hormone in each of these samples would be a means for directly determining the ability of the patient's pituitary to release growth hormone.
Accordingly, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of Formula I in association with a pharmaceutical carrier or diluent. Optionally, the active ingredient of the pharmaceutical compositions can comprise a growth promoting agent in addition to at least one of the compounds of Formula I or another composition which exhibits a different activity, e.g., an antibiotic or other
pharmaceutically active material.
Growth promoting agents include, but are not limited to, TRH, diethylstilbesterol, theophylline, enkephalins, E series prostaglan- dins, compounds disclosed in U.S. Patent No. 3,239,345, e.g., zeranol, and compounds disclosed in U.S. Patent No. 4,036,979, e.g., sulbenox or peptides disclosed in U.S. Patent No. 4,411,890.
A still further use of the disclosed novel substituted dipeptide analogs is in combination with other growth hormone secretagogues such as GHRP-6, GHRP-1 as described in U.S. Patent Nos. 4,411,890; and publications WO 89/07110 and WO 89/07111 and B-HT920 or growth hormone releasing factor and its analogs or growth hormone and its analogs or somatomedins including IGF-1 and IGF-2. A still further use of the disclosed novel substituted dipeptide analogs is in combination with α2 adrenergic agonists or β3 adrenergic agonists in the treatment of obesity or in combination with parathyroid hormone or bisphosphonates, such as MK-217 (alendronate), in the treatment of osteoporosis.
As is well known to those skilled in the art, the known and potential uses of growth hormone are varied and multitudinous. Thus, the administration of the compounds of this invention for purposes of stimulating the release of endogenous growth hormone can have the same effects or uses as growth hormone itself. These varied uses of growth hormone may be summarized as follows: stimulating growth hormone release in elderly humans; Prevention of catabolic side effects of glucocorticoids, treatment of osteoporosis, stimulation of the immune system, treatment of retardation, acceleration of wound healing, accelerating bone fracture repair, treatment of growth retardation, treating renal failure or insufficiency resulting in growth retardation, treatment of physiological short stature, including growth hormone deficient children, treating short stature associated with chronic illness, treatment of obesity and growth retardation associated with obesity, treating growth retardation associated with Prader-Willi syndrome and Turner's syndrome; Accelerating the recovery and reducing
hospitalization of burn patients; Treatment of intrauterine growth retardation, skeletal dysplasia, hypercortisolism and Cushings
syndrome; Induction of pulsatile growth hormone release; Replacement of growth hormone in stressed patients; Treatment of osteochondrodysplasias, Noonans syndrome, schizophrenia, depression, Alzheimer's disease, delayed wound healing, and psychosocial deprivation; treatment of pulmonary dysfunction and ventilator dependency; Attenuation of protein catabolic response after a major operation; reducing cachexia and protein loss due to chronic illness such as cancer or AIDS.
Treatment of hyperinsulinemia including nesidioblastosis; Adjuvant treatment for ovulation induction; To stimulate thymic development and prevent the age-related decline of thymic function; Treatment of immunosuppressed patients; Improvement in muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis, renal hemeostasis in the frail elderly; Stimulation of osteoblasts, bone remodelling, and cartilage growth; Stimulation of the immune system in companion animals and treatment of disorders of aging in companion animals;
Growth promotant in livestock; and stimulation of wool growth in sheep.
The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual, or topical routes of administration and can be formulated in dosage forms appropriate for each route of administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax.
Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 0.0001 to 100 mg/kg. of body weight daily are administered to patients and animals, e.g., mammals, to obtain effective release of growth hormone.
The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the disclosed invention.
EXAMPLE 1
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H-tetrazol-5- yl)[ 1,1'-biphenyl]-4-yl]methyl]benzene-butanamide, trifluoroacetate
Step A: 5-Phenyltetrazole
Zinc chloride (3.3 g, 24.3 mmol, 0.5 eq) was added to 15 mL of N,N-dimethylformamide in small portions while maintaining the temperature below 60°C. The suspension of zinc chloride was cooled to room temperature and treated with 5.0 g of benzonitrile (48.5 mmol, 1.0 eq) followed by 3.2 g of sodium azide (48.5 mmol, 1.0 eq). The heterogeneous mixture was heated at 115°C with agitation for 18 hours. The mixture was cooled to room temperature, water (30 mL) was added and the mixture acidified by the addition of 5.1 mL of concentrated hydrochloric acid. The mixture was cooled to 0°C and aged for one hour, then filtered and the filter cake washed with 15 mL of cold 0.1N HCl then dried at 60°C under vacuum to afford 6.38 g (43.7 mmol, 90%) of the product.
Step B: 5-Phenyl-2-trityltetrazole
To a suspension of 5.0 g (34.2 mmol) of 5-phenyltetrazole in 55 mL of acetone was added 5.0 mL of triethylamine (3.6 g, 35.6 mmol, 1.04 eq). After 15 minutes, a solution of 10.0 g of triphenyl- methyl chloride (35.9 mmol, 1.05 eq) in 20 mL of tetrahydrofuran was added and the mixture stirred at room temperature for one hour. Water (75 mL) was slowly added and the mixture stirred for one hour at room temperature. The product was collected by filtration, washed with 75 mL of water and dried at 60°C under vacuum to give 13.3 g (34.2 mmol, 100%) of the product.
Step C: N-Triphenylmethyl-5-[2-(4'-methylbiphen-4-yl)]tetrazole
A solution of zinc chloride (6.3 g, 46.2 mmol, 0.6 eq) in 35 mL of tetrahydrofuran was dried over molecular sieves. 5-Phenyl-2- trityltetrazole (30.0 g, 77.3 mmol, 1.0 eq) was dissolved in 300 mL of dry tetrahydrofuran and the solution gently stirred while being degassed three times by alternating vacuum and nitrogen purges. The stirred solution was cooled to -15°C and treated slowly with 50.5 mL of 1.6 M n-butyllithium in hexane (80.0 mmol, 1.05 eq) so as to maintain the temperature below -5°C. The solution was maintained at -5 to -15°C for 1.5 hours then treated with the dried zinc chloride solution and allowed to warm to room temperature.
In a separate flask, 4-iodotoluene (20.17 g, 92.5 mmol, 1.2 eq) and bis(triphenylphosphine)nickel(II)dichloride (1.5 g, 2.3 mmol, 0.03 eq) were dissolved in 60 mL of tetrahydrofuran, then degassed and left under an atmosphere of nitrogen. The mixture was cooled to 5°C and treated with 1.5 mL of 3.0 M solution of methylmagnesium chloride in tetrahydrofuran (4.5 mmol, 0.06 eq) so as to keep the temperature below 10°C. The solution was warmed to room temperature and added, under nitrogen purge, to the arylzinc solution. The reaction mixture was stirred vigorously for 8 hours at room temperature then quenched by the slow addition of a solution of 10 mL of glacial acetic acid (1.6 mmol, 0.02 eq) in 60 mL of tetrahydrofuran at a rate so that the temperature was maintained below 40°C. The mixture was stirred for 30 minutes and 150 mL of 80% saturated aqueous sodium chloride was added; the reaction mixture was extracted for 30 minutes and the layers allowed to separate. The organic layer was removed and washed with 150 mL of 80% saturated aqueous sodium chloride buffered to pH >10 by the addition of ammonium hydroxide. The organic phase was removed and concentrated under vacuum to approximately 50 mL then 250 mL of acetonitrile was added. The mixture was again concentrated under vacuum to 50 mL and acetonitrile added to make the final volume 150 mL. The resulting slurry was cooled at 5°C for 1 hour then filtered and washed with 50 mL of cold acetonitrile followed by 150 mL of distilled water. The filter cake was air dried to a free flowing solid then further dried
under vacuum at 50°C for 12 hours to afford 30.0 g (62.8 mmol, 81 %) of the product. 1H NMR (200 MHz, CDCl3): 2.28 (s,3H), 6.9-7.05 (m, 10H), 7.2-7.5 (m, 12H), 7.9 (m, 1H).
Step D: N-Triphenylmethyl-5-[2-(4'-bromomethylbiphen4- yl]tetrazole
A solution of 3.15 g (6.6 mmol) of N-triphenylmethyl-5- [2-(4'-methylbiphen-4-yl)]tetrazole in 25 mL of methylene chloride was treated with 1.29 g (7.25 mmol, 1.1 eq) of N-bromosuccinimide, 80 mg (0.5 mmol, 0.07 eq) of AIBN, 200 mg of sodium acetate and 200 mg of acetic acid. The mixture was heated at reflux for 16 hours then cooled and washed with saturated aqueous sodium bicarbonate. The organic layer was removed, dried over sodium sulfate, filtered and concentrated to a minimum volume by atmospheric distillation. Methyl t-butyl ether was added and distillation continued until almost all the methylene chloride was removed the the total volume reduced to approximately 12 mL and 12 mL of hexanes was then added. The mixture was kept at room temperature for 2 hours and the product isolated by filtration, washed with hexanes then dried under vacuum at 50°C to give 2.81 g (5.04 mmol, 76%) of the product. 1H NMR (200 MHz, CDCl3): 4.38 (s, 2H), 6.9-8.0 (m, 23H). NMR indicates presence of approximately 1 % of the starting material and 7% of the dibromo derivative.
Step E: N-Triphenylmethyl-5-[2-(4'-azidomethylbiphen-4- yl]tetrazole
To 5.57 g (10 mmol) of N-triphenylmethyl-5-[2-(4'- bromomethylbiphen-4-yl)]tetrazole in 20 mL of dimethyl sulfoxide was added 614 mg (12.5 mmol, 1.25 eq) of pulverized lithium azide. The reaction was stirred at room temperature for 4 hours, during which time a thick precipitate formed. The precipitated solids were collected by filtration and washed with methanol, water, and then methanol again, and dried under vacuum for 16 hours to yield 4.06 g (78%) of the product as a white solid. 1H NMR (200 MHz, CDCl3): 3.46 (s, 2H), 6.82-7.55 (m, 22H), 7.95 (m, 1H).
Step F: N-Triphenylmethyl-5-[2-(4'-aminomethylbiphen-4- yl]tetrazole
To a solution of 4.06 g (7.8 mmol) of N-triphenylmethyl- 5-[2-(4'azidomethylbiphen-4-yl)]-tetrazole in 15 mL of tetrahydrofuran was added 2.05 g (7.8 mmol, 1 eq) of triphenylphosphine in small portions. The mixture was stirred at room temperature for 2 hours, at which time 0.2 mL of water was added and the reaction mixture stirred for 16 hours. The reaction mixture was concentrated to dryness under vacuum and the crude product chromatographed on a silica flash column, eluting with chloroform, to give 1.5 g (3.03 mmol, 39%) of the product. 1H NMR (200 MHz, CDCl3): 2.21 (br s, 2H), 3.75 (s, 2H), 6.80-7.94 (m, 22H), 7.94 (m, 1H).
Step G: (R)-α-[t-Butoxycarbonylamino]-N-[[2'-(N-triphenyl- methyl-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]benzene- butanamide
To a solution of 30.5 mg (0.11 mmol) of N-BOC-D- homophenylalanine in 1 mL of methylene chloride at room temperature under a nitrogen atmosphere was added 54 mg (0.11 mmol, 1 eq) of N- triphenylmethyl-5-[2-(4'aminomethylbiphen-4-yl)]tetrazole (Step F), 25 mg (0.13 mmol, 1.2 eq) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 13 mg (0.13 mmol, 1.2 eq) of triethylamine. The reaction was stirred at room temperature for 16 hours, then transferred to a separatory funnel and washed with 2 mL of 5% aqueous citric acid and 2 mL of saturated aqueous sodium bicarbonate. The organic layer was removed, dried over magnesium sulfate, filtered and evaporated to dryness under vacuum. The residue was chromato graphed on a silica flash column, eluting with hexane/ethyl acetate (5: 1), to give 29 mg (35%) of the product. 1H NMR (200 MHz, CDCl3):
1.43 (s, 9H), 2.05 (m, 2H), 2.67 (t, 8Hz, 2H), 4.05 (m, 1H), 4.32 (m, 1H), 4.99 (m, 1H), 6.19 (m, 1H), 6.78-7.15 (m, 27H), 7.95 (m, 1H).
Step H: (R)-α-[t-Butoxycarbonylamin o]-N-[[2'-(1H-tetrazol-5- yl)[1 ,1 '-biphenyl]-4-yl ]methyl]-benzene-butanamide
A solution of 29 mg (0.038 mmol) of the intermediate obtained in Step G in 1 mL of methanol was hydrogenated at room temperature and one atmosphere over 4 mg of 20% palladium
hydroxide on carbon for two hours. The reaction mixture was then filtered through Celite to remove the catalyst, the solvent removed under vacuum and the residue flash chromatographed on silica to yield 19 mg (95%) of the title compound. 1H NMR (200 MHz, CD3OD): 1.43 (s, 9H), 1.95 (m, 2H), 2.64 (m, 2H), 4.00 (m, 1H), 4.34 (t, 5Hz, 2H), 7.00-7.30 (m, 8H), 7.50 (m, 5H). FAB-MS: calculated for
C29H32N6O3 512; found 513 (M+1, 24%).
Step I; (R)-α-Amino-N-[[2'-(1H-tetrazol-5-yl)[1,1 '-biphenyl]-
4yl]methyl]-benzenebutanamide, hydrochloride
A solution of 19 mg (0.037 mmol) of the intermediate obtained in Step H in 1 mL of methanol was treated with one drop of concentrated hydrochloric acid. The mixture was stured at room temperature for 16 hours then evaporated to dryness under vacuum. The crude product was purified on reverse phase HPLC on C18, eluting with methanol/0.1% aqueous trifluoroacetic acid [linear gradient: 60% methanol to 80% methanol over 10 minutes], to yield 14 mg (84%) of the product. 1H NMR (200 MHz, CD3OD): 2.1 1 (m, 2H), 2.64 (m, 2H), 3.89 (t, 6Hz, 1H), 4.42 (s, 2H), 7.05-7.32 (m, 8H), 7.58 (m, 5H). FAB-MS: calculated for C24H24N6O 412; found 413 (M+1, 100%).
Step J: 2.2-Dimethylbutanedioic acid, 4-methyl ester
2,2-Dimethylsuccinic acid (20 g, 137 mmol) dissolved in 200 mL of absolute methanol at 0°C was treated dropwise with 2 mL of concentrated sulfuric acid. After the addition was complete, the mixture was allowed to warm to room temperature and stir for 16 hours. The mixture was concentrated under vacuum to 50 mL and slowly treated with 200 mL of saturated aqueous sodium bicarbonate. The mixture was washed with hexane (3x) and the aqueous layer removed and cooled in an ice bath. The mixture was acidified to pH 2 by slow addition of 6N HCl then extracted with ether (8x). The combined extracts were washed with brine, dried over magnesium sulfate, filtered and solvents removed under vacuum. The residue was dried at room temperature under vacuum to afford 14.7 g (91.8 mmol, 67%) of the product as a viscous oil that slowly solidified upon standing. 1H NMR (200 MHz, CDCl3): 1.29 (s, 6H), 2.60 (s, 2H), 3.65 (s, 3H).
Step K: 3-Benzyloxycarbonylamino-3-methylbutanoic acid, methyl ester
To 14.7 g (91.8 mmol) of 2,2-dimethylbutanedioic acid-4- methyl ester in 150 mL of benzene was added 13 mL of triethylamine (9.4 g, 93 mmol) followed by 21.8 mL of diphenylphosphoryl azide (27.8 g, 101 mmol). The mixture was heated under nitrogen at reflux for 45 minutes then 19 mL (19.9 g, 184 mmol) of benzyl alcohol was added and refluxing continued for 16 hours. The mixture was cooled, filtered and the filtrate concentrated to a minimum volume under vacuum. The residue was redissolved in 250 mL of ethyl acetate, washed with water, saturated aqueous sodium bicarbonate (2x) and brine. The organic layer was removed, dried over magnesium sulfate, filtered and the filtrate concentrated to a minimum volume under vacuum. The crude product was purified by medium pressure liquid chromatography on silica, eluting with hexane/ethyl acetate (4:1), to afford 18.27 g (68.9 mmol, 75%) of the product. 1H NMR (200 MHz, CDCl3): 1.40 (s, 6H), 2.69 (s, 2H), 3.63 (s, 3H), 5.05 (s, 2H), 5.22 (br s, 1H), 7.32 (s, 5H).
Step L: 3-Benzyloxycarbonylamino-3-methylbutanoic acid A solution of 18.27 g (68.9 mmol) of 3-benzyloxycar- bonylamino-3-methylbutanoic acid methyl ester in 20 mL of methanol at room temperature was treated dropwise with 51 mL of 2N NaOH (102 mmol). The mixture was stined at room temperature for 16 hours then transferred to a separatory funnel and washed with hexane (3x). The aqueous layer was removed, cooled to 0°C and slowly acidified to pH 2 (paper) by dropwise addition of 6N HCl. This mixture was extracted with ether (6x); combined extracts were washed with 1N HCl and brine, then dried over magnesium sulfate, filtered and solvent removed under vacuum to afford 17.26 g (68.7 mmol, 99%) of the product. 1H NMR (200 MHz, CDCl3): 1.42 (s, 6H), 2.77 (s, 2H), 5.06 (s, 2H), 5.2 (br s, 1H), 7.3 (s, 5H).
Step M: 3-Benzyloxycarbonylamino-3-methylbutanoic acid, N- hydroxysuccinimide ester
A solution of 2.93 g (11.7 mmol, 0.85 eq) of 3-benzyl- oxycarbonylamino-3-methy lbutanoic acid in 5 mL of methylene chloride at room temperature was treated with 1.61 g (14.0 mmol) of N-hydroxysuccinimide followed by 2.67 g (14.0 mmol, 1 eq) of 1(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. The reaction mixture was stined for 16 hours then transferred to a separatory funnel, washed with water and dilute aqueous sodium bicarbonate. The organic layer was removed, dried over magnesium sulfate, filtered, and solvents removed under vacuum. The crude product was chromatographed on a silica flash column, eluting with hexane/ethyl acetate (1 :1), to give 3.9 g (quantitative) of the product. 1H NMR (200 MHz, CDCl3): 1.51 (s, 6H), 2.80 (s, 4H), 3.12 (s, 2H), 5.13 (s, 2H), 7.37 (s, 5H). FAB-MS: calculated for C17H20N2O6 348; found 349 (M+1, 40%).
Step N: (R)-α-[(3-Benzyloxycarbonylamino-3-methyl-1-oxo- butyl)amino]-N-[[2'-(1H-tetrazol-5-yl)-[1 ,1 '-biphenyl]- 4yl]methyl]benzenebutanamide A solution of 12 mg (0.023 mmol) of the intermediate obtained in Step I in 0.5 mL of methylene chloride at room temperature was treated with 9.2 mg (0.027 mmol, 1.2 eq) of 3-benzyloxy- carbonylamino-3-methylbutanoic acid, N-hydroxysuccinimide ester (Step M) and 3.5 mg (0.027 mmol, 1.2 eq) of diisopropylethylamine. The reaction mixture was stirced at room temperature for 48 hours. Solvents were emoved under vacuum and the crude residue was purified on HPLC to give 14 mg of product. 1H NMR (200 MHz, CD3OD): 1.29 (s, 3H), 1.36 (s, 3H), 1.90 (m, 3H), 2.45 (m, 3H), 4.31 (m, 1H), 4.72 (d, 20Hz, 1H), 5.02 (d, 20Hz, 1H), 7.00-7.62 (m, 18H). FAB-MS: calculated for C37H39N7O4 645; found 646 (M+1, 100%).
Step O: (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]benzenebutana- mide. tri-fluoroacetate
A solution of 14 mg (0.21 mmol) of the intermediate obtained in Step N in 1 mL of methanol was hydrogenated at room temperature and one atmosphere over 1 mg of 20% palladium
hydroxide on carbon for 16 hours. The reaction mixture was filtered through Celite and the filtrate concentrated under vacuum and the residue chromatographed on reverse phase high pressure liquid chromatography on C18, eluting with methanol/0.1% aqueous
trifluoroacetic acid (linear gradient; 65% methanol increased to 85% over 10 minutes), to give 10 mg (72%) of the title compound. 1H NMR (200 MHz, CD3OD): 1.32 (s, 3H), 1.36 (s, 3H), 1.81 (m, 1H), 1.95 (m, 2H), 2.26 (m, 1H), 2.52 (s, 1H), 2.63 (m, 1H), 4.34 (m, 1H), 4.76 (d, 14Hz, 1H), 4.95 (d, 14Hz, 1H), 7.01-7.70 (m, 13H). FAB-MS:
calculated for C29H33N7O2 511 ; found 512 (M+1, 100%).
EXAMPLE 2
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H-tetrazol-5- yl)[ 1 ,1 '-biphenyl ]-4-yl ]methyl]benzene-propanamide, trifluoroacetate The title compound was prepared from N-BOC-D- phenylalanine by the methods described in Example 1. 1H NMR (200 MHz, CDCl3): 1.27 (s, 3H), 1.40 (s, 3H), 2.49 (d, 15Hz, 1H), 2.62 (d, 15Hz, 1H), 3.10 (m, 2H), 4.44 (m, 2H), 4.80 (m, 1H), 7.16 (s, 4H), 7.35 (s, 5H); 7.70 (m, 4H). FAB-MS: calculated for C28H3 1N7O2 497; found 498 (M+1, 100%).
EXAMPLE 3
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H-tetrazol-5- yl)[1,1'-biphenyl]-4-yl]methyl]-1H-indole-3-propanamide,
trifluoroacetate
Step A: (R)-α-[t-Butoxycarbonylamino]-N-[[2'-(N-triphenyl- memyl-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(Nim- formyl)indole-3-propanamide
Prepared from N-triphenylmethyl-5-[2-(4'-aminomethyl- biphen-4-yl)]tetrazole and Nim-formyl-Nα-BOC-D-tryptophan by the procedure described in Example 1 , Step G. 1H NMR (200 MHz,
CDCl3): 1.40 (s, 9H), 3.18 (br s, 2H), 4.24 (br s, 2H), 4.48 (m, 1H), 5.24 (s, 1H), 6.28 (s, 1H), 6.70-7.70 (m, 27H), 7.90 (m, 1H), 8.82 (br s, 1H).
Step B: (R)-a-[t-Butoxycarbonylamino]-N-[[2'-(1H-tetrazol-5- yl)[1,1'-biphenyl]-4-yl]methyl]-(Nim-formyl)indole-3- propanamide
Prepared from the intermediate obtained in Step A by the procedure described in Example 1, Step H. 1H NMR (200 MHz,
CD3OD): 1.38 (s, 9H), 3.14 (m, 3H), 6.90-7.70 (m, 13H), 9.02 (br s, 1H). FAB-MS: calculated for C30H31N7O4 553; found 554
(M+1, 40%). Step C: (R)-α-Amino-N-[[2'-(1H-tetrazol-5-yl)[1 ,1 '-biphenyl]-4- yl]methyl]-(Nim-formyl)indole-3-propanamide, trifluoroacetate
A solution of 80 mg (0.14 mmol) of the intermediate obtained in Step B in 4 mL methylene chloride was treated with 1 mL of anisole followed by 4 mL of trifluoroacetic acid. The reaction mixture was stirred at room temperature for 1 hour, then all volatiles were removed under vacuum. The residue was purified by reverse phase high pressure liquid chromatography on C18, eluting with
methanol/0.1 % aqueous trifluoroacetic acid (45:55), to give 64 mg (77%) of the product. 1H NMR (200 MHz, CD3OD): 3.26 (m, 2H), 4.11 (t, 6Hz, 1H), 4.28 (m, 2H), 6.99 (s, 4H), 7.28-7.70 (m, 9H), 8.75 (br s, 1H). FAB-MS: calculated for C26H23N7O2 465; found 466 (M+1, 22%).
Step D: 4,4-Dimethylazetidin-2-one
A 3-neck 3L round bottom flask equipped with a magnetic stiner, thermometer, cold finger condenser and nitrogen bubbler was charged with 1L of ether. The flask was cooled to -65°C and into it was condensed 500-600 mL of isobutylene. The cold finger condenser was replaced with a dropping funnel and 200 mL (325 g, 2.30 mol) of chlorosulfonyl isocyanate was added dropwise over 1.5 hours. The mixture was maintained at -65°C for 1.5 hours then the dry ice/acetone cooling bath replaced with methanol/ice and the internal temperature slowly increased to -5°C at which time the reaction initiated and the internal temperature rose to 15°C with evolution of gas. The internal temperature remained at 15°C for several minutes then dropped back down to -5°C and the mixture stirred at -5°C for 1 hour. The
methanol/ice bath was removed and the reaction mixture warmed to room temperature and stirred overnight.
The reaction mixture was transferred to a 3-neck 12L round bottom flask fitted with a mechanical stiner and diluted with 2L of ether. The well-stined reaction mixture was treated with 2L of saturated aqueous sodium sulfite. After 1 hour, an additional 1L of saturated aqueous sodium sulfite was added followed by sufficient sodium bicarbonate to adjust the pH to approximately 7. The mixture was stirred another 30 minutes then the layers allowed to separate. The ether layer was removed and the aqueous layer reextracted with 2 x 1 L of ether. The combined ether extracts were washed once with 500 mL of saturated aqueous sodium bicarbonate and once with 500 mL of saturated aqueous sodium chloride. The ether layer was removed, dried over magnesium sulfate, filtered and concentrated under vacuum to give 33 g of a pale yellow oil. The aqueous layer was made basic by the addition of solid sodium bicarbonate and extracted with 3 x 1L of ether. The combined ether extracts were washed and dried as described above, then combined with the original 33 g of pale yellow oil and concentrated under vacuum to give 67.7 g of product. Further extraction of the aqueous layer with 4 x 1L of methylene chloride and washing and drying as before gave an additional 74.1 g of product. Still further extraction of the aqueous layer with 4 x 1L of methylene chloride gave an additional 21.9 g of product. The combined product (163.7 g, 1.65 mol, 72%) was used in Step E without purification. 1H NMR (200 MHz, CDCl3): 1.45 (s, 6H), 2.75 (d, 3Hz, 2H), 5.9 (br s, 1H).
Step E: N-(t-Butoxycarbonyl)-4,4-dimethylazetidin-2-one
A 5L, 3-neck round bottom flask equipped with a magnetic stiner, thermometer, nitrogen bubbler and addition funnel was charged with 88.2 g (0.89 mol) of 4,4-dimethylazetidin-2-one, 800 mL of methylene chloride, 150 mL of triethylamine (1.08 mol) and 10.9 g (0.089 mol) of 4-dimethylaminopyridine. To the stined solution at room temperature was added dropwise over 15 minutes a solution of 235 g (1.077 mol) of di-t-butyl-dicarbonate in 300 mL of methylene chloride. The reaction mixture was stined at room temperature overnight then diluted with 1L of methylene chloride and washed with 500 mL of saturated aqueous ammonium chloride, 500 mL of water, and 500 mL of saturated aqueous sodium chloride. The organic layer was separated, dried over magnesium sulfate, filtered and concentrated under vacuum to afford 180.3 g of crude product as an orange solid.
The material was used directly in Step F without purification.
1H NMR (200 MHz, CDCl3): 1.50 (s, 9H), 1.54 (s, 6H), 2.77 (s, 2H).
Step F: 3-t-Butoxycarbonylamino-3-methylbutanoic acid
A 3L, 3-neck round bottom flask equipped with a magnetic stiner, thermometer, nitrogen bubbler and addition funnel was charged with 180.3 g (0.89 mol) of N-(t-butoxycarbonyl)-4,4-dimethylazetidin- 2-one dissolved in 1L of tetrahydrofuran. The solution was cooled to 0- 5°C and treated dropwise with 890 mL of 1.0M aqueous lithium hydroxide over 30 minutes. The reaction mixture was stined at 0-5°C for 2 hours then diluted with 1L of ether and 1L of water. The layers were allowed to separate and the aqueous layer was reextracted with an additional 1L of ether. The aqueous layer was acidified by the addition of 1L of saturated aqueous sodium bisulfate, then extracted with 1 x 1L and 2 x 500 mL of ether. The combined organic layer and ether extracts were washed with 500 mL of saturated aqueous sodium
chloride, dried over magnesium sulfate and concentrated under vacuum to give 173 g of a yellow oil that solidified upon standing. The material was slurried with warm hexane then filtered and dried under high vacuum to afford 168.5 g (0.775 mol, 87%) of product as a white solid. 1H NMR (200 MHz, CDCl3): 1.39 (s, 6H), 1.44 (s, 9H), 2.72 (s, 2H). FAB-MS: calculated for C10H19NO4 217; found 218 (M+H, 54%).
Step G: (R)-α-[(3-t-Butoxycarbonylamino-3-methyl-1-oxo- butyl)amino]-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4- yl ]methy] - ( Nim -formyl)-indole-3-propanamide
A solution of 64 mg (0.11 mmol) of the intermediate obtained in Step C in 1 mL of methylene chloride at 0°C was treated with 25 mg (0.12 mmol, 1.1 eq) of dicyclohexylcarbodiimide and the resulting solution stined at 0°C for 30 minutes. A solution of 53 mg (0.24 mmol, 2 eq) of 3-t-butoxycarbonylamino-3-methylbutanoic acid and 12 mg (0.12 mmol, 0.017 mL, 1.1 eq) of triethylamine in 1 mL of methylene chloride was added and the mixture stirred for 5 hours at room temperature. The reaction mixture was evaporated to dryness under vacuum and the residue was dissolved in 1 mL of anisole and treated with 4 mL of trifluoroacetic acid. The mixture was stined at room temperature for 30 minutes the concentrated under vacuum. The residue was taken up in methanol and the solids removed by filtration. The filtrate was concentrated under vacuum; the residue was purified by reverse phase high pressure liquid chromatography on C18 to yield 31 mg (42%) of the product. 1H NMR (200 MHz, CD3OD): 1.14 (s, 3H), 1.25 (s, 3H), 2.37 (d, 15Hz, 1H), 2,48 (d, 15Hz, 1H), 3.11 (m, 2H), 4.26 (m, 2H), 4.72 (m, 1H), 6.92-7.70 (m, 13H), 8.55 (br s, 1H).
FAB-MS: calculated for C31H32N8O3 564; found 565 (M+1, 80%).
Step H: (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-y1)[1,1'-biphenyl]-4-yl]methyl]-1H-indole-3- propanamide, trifluoroacetate
A solution of 31 mg (0.046 mmol) of the intermediate obtained in Step G in 1 mL of methanol was treated with 0.2 mL of concentrated hydrochloric acid and the resulting mixture heated at 65°C for 1.5 hours. All volatiles were removed under vacuum and the residue purified by reverse phase high pressure liquid chromatography on C18, eluting with methanol/0.1 % aqueous trifluoroacetic acid
(50:50), to give 20 mg (67%) of the title compound. 1H NMR (200 MHz, CD3OD): 1.15 (s, 3H), 1.28 (s, 3H), 2.38 (d, 16Hz, 1H), 2.50 (d, 16Hz, 1H), 3.19 (m, 2H), 4.20 (d, MHz, 1H), 4.32 (d, 14Hz, 1H), 4.73 (t, 7Hz, 1H), 6.90-7.70 (m, 13H). FAB-MS: calculated for
C30H32N8O2 536; found 536 (70%).
EXAMPLE 4
(R)-2-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-phenyl-N-[[2'-(1H- tetrazol-5-yl)[ 1,1 '-biphenyl]-4-yllmethyl]-butanamide, trifluoroacetate
Step A: (R)-2-(t-Butoxycarbonylamino)-N-phenyl-butanamide Prepared from N-BOC-D-2-aminobutanoic acid and aniline by the method described in Example 1, Step G. 1H NMR (200 MHz, CDCl3): 1.00 (t, 6Hz, 3H), 1.45 (s, 9H), 1.82 (m, 2H), 4.30 (m, 1H), 5.59 (d, 7Hz, 1H), 7.00-7.62 (m, 5H), 8.90 (br s, 1H). FAB-MS:
calculated for C15H22N2O3 278; found 279 (M+1, 40%).
Step B: (R)-2-(t-Butoxycarbonylamino)-N-phenyl-N-[[2'-(N- triphenylmethyl-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]- butanamide
A solution of 70 mg (0.25 mmol) of (R)-2-(t-butoxy- carbonylamino)-N-phenyl-butanamide in 0.5 mL of dry dimethyl- formamide was treated with 10 mg (0.25 mmol, 1 eq) of 60% sodium hydride oil dispersion. The mixture was stined at room temperature for 20 minutes, then treated with a solution of 140 mg (0.25 mmol, 1 eq) of N-triphenylmethyl-5-[2-(4'-bromomethylbiphen-4-yl)]tetrazole (Example 1, Step D) in 0.5 mL of dry dimethylformamide. The mixture was stirred at room temperature for 2 hours, then quenched by the addition of 2 mL of water. The mixture was extracted several times with ethyl acetate; the combined extracts were washed with 5% aqueous citric acid, saturated aqueous sodium bicarbonate then dried over magnesium sulfate, filtered and the filtrate dried under vacuum. The crude material was chromatographed on a flash silica column, eluting with hexane/ethyl acetate (1:1), to give 91 mg (48%) of the product. 1H NMR (200 MHz, CDCl3): 0.74 (t, 6Hz, 3H), 1.32 (s, 9H), 1.58 (m, 2H), 4.20 (m, 1H), 4.79 (s, 2H), 6.82-7.60 (m, 27H), 7.86 (m, 1H).
Step C: (R)-2-(t-Butoxycarbonylamino)-N-phenyl-N-[[2'-(1H- tetrazol-5-yl)-[1,1'-biphenyl]-4-yllmethyl]butanamide
Prepared from the intermediate obtained in Step B by the procedure described in Example 1, Step H. 1H NMR (200 MHz, CDCl3): 0.74 (t, 6Hz, 3H), 1.36 (s, 9H), 1.55 (m, 2H), 4.13 (m, 1H), 4.70 (d, 14Hz, 1H), 5.02 (d, 14Hz, 1H), 5.22 (m, 1H), 7.00-7.62 (m, 12H), 8.01 (m, 1H). FAB-MS: calculated for C29H32N6O3 512; found 513 (M+1, 100%). Step D: (R)-2-Amino-N-phenyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl]butanamide, hvdrochloride
Prepared from the intermediate obtained in Step C by the method described in Example 1 , Step I. 1H NMR (200 MHz, CD3OD): 0.83 (t, 7Hz, 3H), 1.68 (m, 2H), 3.80 (m, 1H), 4.81 (d, 14Hz, 1H), 5.01 (d, MHz, 1H), 7.00-7.70 (m, 13H). FAB-MS: calculated for
C24H24N6O 412; found 413 (M+1, 100%).
Step E: 3-t-Butoxycarbonylamino-3-methylbutanoic acid, N- hydroxysuccinimide ester
Prepared from 3-t-butoxycarbonylamino-3-methylbutanoic acid (Example 3, Step F) and N-hydroxysuccinimde by the procedure describe in Example 1, Step M. 1H NMR (200 MHz, CDCl3): 1.41 (s, 9H), 1.43 (s, 6H), 2.82 (s, 4H), 3.07 (s, 2H), 4.72 (br s, 1H).
Step F: (R)-2-[(3-t-Butoxycarbonylamino-3-methyl-1-oxobutyl)- amino]-N-phenyl-N-[[2'-(1H-tetra-zol-5-yl)[1,1'-biphenyl]-
4yl]methyl]-butanamide
Prepared as in Example 1, Step N from (R)-2-amino-N- phenyl-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]butanamide, hydrochloride and 3-t-butoxycarbonylamino-3-methylbutanoic acid, N- hydroxysuccinimide ester. 1H NMR (200 MHz, CD3OD): 0.74 (t, 7Hz, 3H), 1.32 (s, 6H), 1.40 (s, 9H), 1.58 (m, 2H), 2.45 (d, 13Hz, 1H), 2.58 (d, 13Hz, 1H), 4.29 (m, 1H), 4.78 (d, 14Hz, 1H), 4.95 (d, 14Hz, 1H), 6.97-7.79 (m, 13H). FAB-MS: calculated for C34H41N7O4 611 ; found 612 (M+1, 100%).
Step G: (R)-2-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-phenyl-N- [[2'-(1H-tetrazol-5-yl)[1,1 '-biphenyl]-4-yl]methyl]- butanamide, trifluoroacetate
The title compound was prepared from the intermediate obtained in Step F by the procedure described in Example 3, Step H. 1H NMR (200 MHz, CD3OD): 0.72 (t, 7Hz, 3H), 1.32 (s, 3H), 1.40 (s, 3H), 1.58 (m, 2H), 2.51 (m, 2H), 4.28 (m, 1H), 4.73 (d, 14Hz, 1H), 4.99 (d, 14Hz, 1H), 6.95-7.83 (m, 13H). FAB-MS: calculated for C29H33N7O2 511; found 512 (M+1, 100%).
EXAMPLE 5
2-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H-tetrazol-5- yl)[1 ,1' -biphenyl]-4-yl ]methyl ]acetamide, trifluoroacetate
Step A: 2-t-Butoxycarbonylamino-N-[[2'-(N-triphenylmethyl- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]acetamide
Prepared from N-triphenylmethyl-5-[2-(4'-aminomethyl- biphen-4-yl)]tetrazole (Example 1, Step F) and N-BOC-glycine by the procedure described in Example 1 , Step G. 1H NMR (200 MHz, CDCl3): 1.43 (s, 9H), 3.72 (d, 5Hz, 2H), 4.32 (d, 6Hz, 2H), 5.06 (m, 1H), 6.30 (m, 1H), 6.82-7.68 (m, 22H), 7.95 (m, 1H).
Step B: 2-t-Butoxycarbonylamino-N-[[2'-(1H-tetrazol-5-yl)[1 ,1'- biphenyl]-4-yl]methyl]acetamide
Prepared from the intermediate obtained in Step A by the procedure described in Example 1, Step H. 1H NMR (200 MHz, CD3OD): 1.42 (s, 9H), 3.69 (s, 2H), 4.38 (d, 6Hz, 2H), 6.90-7.28 (m, 4H), 7.42-7.69 (m, 4H). FAB-MS: calculated for C21H24N6O3, 408; found 409 (M+1 , 20%).
Step C: 2-Amino-N-[[2'-(1H-tetrazol-5-yl)[1,1'-bi-phenyl]-4- yl]methyl]acetamide, hydrochloride
Prepared from the intermediate obtained in Step B by the procedure described in Example 1, Step I. 1H NMR (200 MHz, CD3OD): 3.84 (s, 2H), 4.35 (s, 2H), 7.10-7.83 (m, 8H). FAB-MS: calculated for C16H16N6O 308; found 309 (M+1, 100%). Step D: 2-[(3-Benzyloxycarbonylamino-3-methyl-1-oxo-butyl)- amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4yl]- methyl]acetamide
Prepared from the intermediate obtained in Step C and 3- benzyloxycarbonylamino-3-methylbutanoic acid, N-hydroxysuccinimide ester by the procedure described in Example 1, Step N. 1H NMR (200 MHz, CD3OD): 1.37 (s, 6H), 2.60 (s, 2H), 3.79 (s, 2H), 4.33 (s, 2H), 5.00 (s, 2H), 6.95-7.65 (m, 13H). FAB-MS: calculated for
C26H33N7O4 507; found 508 (M+1, 20%).
Step E: 2-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1 ,1'-biphenyl]-4-yl]methyl]acetamide, trifluoroacetate
Prepared from the intermediate obtained in Step D by the procedure described in Example 1, Step O. 1H NMR (200 MHz, CD3OD): 1.38 (s, 6H), 2.52 (s, 2H), 3.89 (s, 2H), 4.38 (s, 2H), 7.00- 7.70 (m, 8H). FAB-MS: calculated for C21H25N7O2 407; found 408 (M+1, 100%).
EXAMPLE 6
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-[[(methyl- amino)carbonyl]amino][1 ,1'-biphenyl]-4-yl]-methyl]-1H-indole-3- propanamide, trifluoroacetate
Step A: N-(t-Butoxycarbonyl)-D-tryptophan benzyl ester
Finely divided t-butoxycarbonyl-D-tryptophan (3 g, 10 mmol) was suspended in methylene chloride and benzyl alcohol (1.08 mL, 10 mmol) and 4-dimethylaminopyridine (0.12 g, 1 mmol) were added and stined at room temperature. Solid 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.92 g, 10 mmol) was then added in three roughly equal portions over 5 minutes. The reaction mixture was stined for 3 hours at room temperature during which time the reaction mixture became a homogeneous solution. The reaction mixture was poured into water (100 mL) and extracted with methylene chloride (2 x 50 mL). The combined methylene chloride layers were washed with 5% aqueous citric acid solution (100 mL) and 5% aqueous sodium bicarbonate solution (100 mL). The resulting methylene chloride layer was dried over magnesium sulfate, filtered and
evaporated under vaccum to give an off-white solid. This solid material was chromatographed on silica gel using ethyl acetate/hexanes (2:3 v/v) as eluant. This afforded 3.56 g (91%) of the desired benzyl ester as a white amorphous powder.
1H NMR (400 MHz, CDCl3): 1.42 (s, 9H), 3.27 (d, 2H), 4.69 (m, 1H), 5.17 (ABq, 2H), 6.78 (br s, 1H), 7.15-7.42 (m, 8H), 7.53 (d, 1H), 7.97 (br s, 1H).
Step B: D-Tryptophan benzyl ester
N-(t-Butoxycarbonyl)-D-tryptophan benzyl ester (3.5 g, 8.87 mmol) was dissolved in methylene chloride (10 mL) and stined at room temperature and trifluoroacetic acid (20 mL) was added dropwise to the ester. The reaction mixture was stined at room temperature for one hour during which time the reaction darkened. The reaction mixture was directly evaporated under vacuum to give a white solid. This solid was dissolved in chloroform (100 mL) and washed with saturated aqueous sodium bicarbonate. The aqueous layer was extracted with chloroform (2 x 25 mL) and the combined chloroform layers were dried over potassium carbonate. Filtration and concentration of the chloroform solution under vacuum gave a pale yellow oil (3.14 g, 82%) which was mainly the desired product.
1H NMR (400 MHz, CDCl3): 1.58 (s, 9H), 3.09 (dd, 1H), 3.27 (dd, 1H), 3.88 (m, 1H), 5.10 (s, 2H), 6.93 (br s, 1H), 7.15-7.39 (m, 8H), 7.59 (d, 1H), 8.03 (br s, 1H).
Step C: (R)-α-[(2-t-Butoxycarbonylamino-2-methyl-1-oxopropyl)- amino]-1H-indole-3-propanoic acid, benzyl ester
Crude D-tryptophan benzyl ester (1.0 g, 3.40 mmol), 1- hydroxybenztriazole hydrate (0.63 g, 4.1 mmol) and t-butoxycarbonyl- α-methylalanine (0.84 g, 4.11 mmol) were stined together at room temperature in chloroform (20 mL). 1-(3-Dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (980 mg, 5.11 mmol) was added to this mixture in a single portion. The reaction mixture was stined at room temperature for 4 hours and worked up by pouring into water (50 mL). The chloroform layer was separated and washed with 5% aqueous citric acid solution (25 mL) and 5% aqueous sodium bicarbonate solution (25 mL). The chloroform layer was dried over magnesium sulfate, filtered and evaporated under vacuum to afford a thick oily foam. Chromatography on silica gel using ethyl acetate/hexanes (2:3 v/v) afforded a yellow foam (0.822 g 50%). 1H NMR (400 MHz, CDCl3): 1.30 (s, 9H), 1.39 (s, 6H), 3.29 (m, 2H), 4.88 (m, 1H), 5.03 (s, 2H), 6.88 (br s, 1H), 7.05-7.35 (m, 8H), 8.53 (d, 1H), 7.98 (br s, 1H).
Step D: (R)-α-[(2-t-Butoxycarbonylamino-2-methyl-1-oxopropyl)- amino]-1H-indole-3-propanoic acid
The benzyl ester (0.82 g, 1.71 mmol) obtained in Step C and 10% palladium on carbon (150 mg) were stined together in ethyl acetate (5 mL). The solution was degassed and a hydrogen atmosphere introduced over the reactants using a balloon for 32 hours. The reaction products were isolated by filtering the reaction mixture through a Celite plug. The plug was washed with additional ethyl acetate (3 x 10 mL). The combined filtrates were evaporated under vacuum to afford the product (680 mg, 102%). 1H NMR (400 MHz, CDCl3): 1.30 (s, 9H), 1.41 (s, 6H), 3.32 (dd, 1H), 3.42 (m, 1H), 4.87 (br s, 1H), 6.82 (d, 1H), 7.13-7.35 (m, 8H), 7.60 (d, 1H), 8.28 (br s, 1H).
Step E: 4-Methyl-2'-nitro-1 ,1 '-biphenyl
A vigorously stined mixture of 34 g (0.25 mol) of 4- tolylboronic acid and 34 g (0.17 mol) of 2-bromo-1-nitrobenzene in a mixture of 170 mL of 5N sodium hydroxide, 57 mL of water, 215 mL of 2-propanol and 1080 mL of benzene was treated with 11.9 g of (tetrakis)triphenylphosphine palladium(0). The two-phase mixture was heated at reflux for three hours. The cooled reaction mixture was filtered through Celite and the filter cake washed with fresh benzene. The organic layer was separated and washed with water (3x), dried over magnesium sulfate and filtered. The filtrate was evaporated under vacuum and the residue (46.1 g) purified by preparative high pressure liquid chromatography on silica gel, eluting with hexane/ethyl acetate (20:1), to give 28.05 g of the product. 1H NMR (400 MHz, CDCl3): 2.38 (s, 3H), 7.20 (m, 4H), 7.43 (m, 2H), 7.59 (t, 1H), 7.8 (d, 1H).
EI-MS: calculated for C13H1 1NO2 213; found 213 (M+).
Step F: 4-Bromomethyl-2'-nitro-1 ,1'-biphenyl
Prepared from 4-methyl-2'-nitro-1 ,1'-biphenyl by the procedure described in Example 1 , Step D. 1H NMR (200 MHz,
CDCl3): 4.53 (s, 2H), 7.2-7.7 (m, 7H), 7.85 (m, 1H).
Step G: 4-Azidomethyl-2'-nitro-1 ,1'-biphenyl
Prepared from 4-bromomethyl-2'-nitro-1 ,1'-biphenyl by the procedure described in Example 1, Step E. 1H NMR (200 MHz,CDCl3 ): 4.39 (s, 2H), 7.2-7.7 (m, 7H), 7.85 (d, 1H).
Step H: 4-Aminomethyl-2'-nitro-1 ,1 '-biphenyl
Prepared from 4-azidomethyl-2'-nitro-1,1'-biphenyl by the procedure described in Example 1, Step E. 1H NMR (200 MHz,
CDCl3): 3.90 (s, 2H), 7.2-7.7 (m, 7H), 7.83 (d, 1H).
Step I: (R)-α-[(2-t-Butoxycarbonylamino-2-methyl-1-oxopropyl)- amino]-N-[[(2'-nitro)[1,1'-biphenyl]-4-yl]methyl]-1H- indole-3-propanamide
The acid (338 mg, 0.87 mmol) from Step D and 4- aminomethyl-2'-nitro-1 ,1'-biphenyl (200 mg, 0.87 mmol) and
triethylamine (0.245 mL, 1.76 mmol) were dissolved in methylene chloride (8 mL) and stined at room temperature. Benzotriazolyl-1- yloxytris(dimethylamino)phosphonium hexafluorophosphate (388 mg, 0.87 mmol) was added in a single portion. The reaction mixture was stined togerther for 3.5 hours then the reaction was quenched by adding saturated aqueous sodium chloride (10 mL) and extracted with methylene chloride (3 x 20 mL). The combined extracts were dried over magnesium sulfate, filtered and evaporated under vacuum. The resulting thick gum was chromatographed on silica gel using ethyl acetate/hexanes (1 :2 v/v) to give 297 mg (50%) of an orange semi-solid. 1H NMR (400 MHz, CD3OD): 1.08 (s, 9H), 1.26 (s, 3H), 1.32 (s, 3H), 3.29 (dd, 1H), 3.43 (dd, 1H), 4.35 (m, 2H), 4.64 (m, 1H), 7.00-7.20 (m, 7H), 7.34 (d, 1H), 7.42 (m, 1H), 7.53 (t, 1H), 7.61 (d, 1H), 7.67 (t, 1H), 7.83 (d, 1H), 8.22 (s, 1H).
Step J: (R)-α-[(2-t-Butoxycarbonylamino-2-methyl-1-oxopropyl)- amino]-N-[[(2'-amino)[1,1'-biphenyl]-4-yl]methyl]-1H- indole-3-propanamide
The amide (142 mg, 0.24 mmol) from Step I was dissolved in ethanol (5 mL) and 10% palladium on carbon (15 mg) was added. The ethanolic mixture was degassed and a hydrogen atmosphere introduced and maintained above the reaction mixture for 2.5 hours using a balloon. The hydrogenation catalyst was removed by filtration through a Celite pad. The pad was washed carefully with methylene chloride (4 x 5 mL). The combined filtrates were evaporated under vacuum to give a powdery white foam (124 mg, 92%). 1H NMR (400 MHz, CD3OD): 1.09 (s, 9H), 1.26 (s, 3H), 1.31 (s, 3H), 3.29 (m, 1H), 3.43 (dd, 1H), 4.36 (m, 2H), 4.62 (m, 1H), 6.87 (m, 2H), 7.00-7.45 (m, 10H), 7.60 (d, 1H), 8.20 (s, 1H). FAB-MS: calculated for
C33H39N5O4 569; found 570 (M+1).
Step K: (R)-α-[(2-t-Butoxycarbonylamino-2-methyl-1-oxopropyl)- amino]-N-[[2'-[[(methylamino)-carbonyl]amino][1 ,1 '- biphenyl]-4-yl]methyl]-1H-indole-3-propanamide
The amine (25 mg, 0.04 mmol) from Step J was dissolved in methylene chloride and methyl isocyanate (0.009 mL, 0.15 mmol) was added to the amine. The reaction mixture was stined together at room temperature for 2.5 hours then the volatiles were removed directly under vacuum. The resultant residue was chromatographed on silica gel using ethyl acetate/hexanes (4:1 v/v) to afford the desired product (23 mg, 82%). 1H NMR (200 MHz, CD3OD): 1.10 (s, 9H), 1.24 (s, 3H), 1.30 (s, 3H), 2.64 (d, 3H), 3.33 (ABq, 2H), 4.33 (m, 2H), 4.60 (m, 1H), 6.23 (m, 1H), 6.96-7.45 (m, 11H), 7.58 (d, 1H), 7.68 (m, 1H), 8.20 (m, 1H). FAB-MS: calculated for C35H42N6O5 626; found 627 (M+1).
Step L: (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-
[(methylaminocarbonyl)amino][1,1'-biphenyl]-4-yl]methyl]-
1H-indole-3-propanamide, trifluoroacetate
The intermediate obtained in Step K (15 mg, 0.023 mmol) and anisole (0.01 mL, 0.09 mmol) were dissolved in methanol (0.5 mL) and hexanes (0.5 mL). To this solution 0.5 mL of 9 N aqueous hydrochloric acid was added. The reactants were stined at room temperature for 30 minutes then the hexane layer was removed using a pipette. The aqueous methanolic layer was evaporated at atmospheric pressure using a fast stream of nitrogen at room temperature. The solid material thus obtained was purified by reverse phase medium pressure liquid chromatography on C8, eluting with methanol/0.1% aqueous trifluoroacetic acid (85:15 v/v). This afforded 11.3 mg (0.018 mmol, 74%) of the title compound. 1H NMR (400 MHz, CD3OD): 1.38 (s, 3H), 1.56 (s, 3H), 2.66 (s, 3H), 3.18 (dd, 1H), 3.33 (dd, 1H), 4.35 (ABq, 2H), 4.78 (t, 1H), 6.98-7.47 (m, 10H), 7.62 (d, 1H), 7.64 (d, 1H). FAB-MS: calculated for C30H34N6O3 526; found 527 (M+1).

Claims (17)

WHAT IS CLAIMED IS:
1. A compound having the formula:
R
where L is
n is 0 or 1;
p is 0 to 6;
q is 0 to 4;
w is 0 or 1 ;
OH R10
I I
X is C=O, O, S(O)m, -CH-, -N-, -CH=CH-;
m is 0 to 2; R1, R2, R1 a, R2a, R1b, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, C1-C3 perfluoroalkoxy, -S(O)m- R7a, cyano, nitro, R7bO(CH2)v-, R7bCOO(CH2)v-, R7bOCO(CH2)v-, R4R5N(CH2)v-, R7bCON(R4)(CH2)v-, R4R5NCO(CH2)v-, R4R5- NCOO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1 -C6 alkoxy, or hydroxy; R7a and R7b are independently hydrogen, C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the phenyl substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy and v is 0 to 3;
R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9, or phenoxy substituted with R9;
R9 is
R7bO(CH2)v-, R7bCOO(CH2)v-, R7bOCO(CH2)v-, R7bCO(CH2)v-, R7bO(CH2)vCO-, R4bR12cN(CH2)v-, R12aR12bNCO(CH2)v-,
R12aR12bNCS(CH2)v-, R4bR12aNN(R12b)CO(CH2)v-,
R4bR12aNN(R12b)CS(CH2)v-, R4bR12aNCON(R12c)(CH2)v-,
R4bR12aNCSN(R12c)(CH2)v-, R4bR12aNN(R12b)CON(R12c)(CH2)v-, R4bR12aNN(R12b)CSN(R12c)(CH2)v-, 4bR12aNN(R12b)-
COO-(CH2)v-, R4bR12aNCOO(CH2)v-, or R13OCON(R12c)(CH2)v-, where v is 0 to 3; R12a, R12b and R12c are independently R5a, OR5a, or COR5a; R12a and R12b, or R12b and R12c, or R12a and R12c, or R4b and R12a, or R4b and R12a, or R4b and R12c, or R13 and R12c, can be taken together to form -(CH2)r-B-(CH2)s- where B is CHR1, O, S(O)m or NR10, m is 0, 1 or 2, r and s are independently 0 to 3 and R1 and R10 are as defined; R13 is C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are hydroxy, -NR10R1 1 , carboxy, phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy or hydroxy where R10 and R1 1 are as defined; R14 is hydrogen, R1, R2 independently disubstituted phenyl, C1-C10 alkyl or substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, C3- C7 cycloalkyl, R1, R2 independently disubstituted phenyl C1-C3 alkoxy, R1, R2 independently disubstituted phenyl, C1-C5 alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl or -NR10R1 1 where R1 , R2, R10 and R1 1 are as defined; R15 is hydrogen, trifluoromethyl, R1, R2 independently disubstituted phenyl, R1, R2 independently disubstituted naphthyl, C3-C7 cycloalkyl, C1-C10 alkyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, C3-C7 cycloalkyl, R1, R2 independently disubstituted phenyl, R1, R2 independently disubstituted phenyl C1-C3 alkoxy, R1, R2 independently disubstituted naphthyl, R1, R2 independently disubstituted naphthyl C1-C3 alkoxy, C1-C5 alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl,
-NR10R1 1 or R1, R2 independently disubstituted heterocycle, where the heterocycle is imidazole, thiophene, furan, pynole, oxazole, thiazole, triazole, tetrazole, pyridine, benzofuran, benzothiophene, benzimidazole, indole, 7-azaindole, oxindole or indazole; where R1, R2, R10 and R1 1 are as defined above. R4, R4a, R4b, R5 and R5a are independently hydrogen, phenyl, substituted phenyl, C1-C10 alkyl, substituted C1-C10 alkyl, C3-C10 alkenyl, substituted C3-C10 alkenyl, C3-C10 alkynyl, or substituted C3- C10 alkynyl where the substituents on the phenyl, alkyl, alkenyl or alkynyl are from 1 to 5 of hydroxy, C1-C6 alkoxy, C3-C7 cycloalkyl, fluoro, R1, R2 independently disubstituted phenyl C1-C3 alkoxy, R1, R2 independently disubstituted phenyl, C1-C20-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, or -NR10R1 1 where R10 and R11 are independently hydrogen, C1 -C6 alkyl, phenyl C1 -C6 alkyl, C1 -C5- alkoxycarbonyl or C1-C5-alkanoyl-C1 -C6 alkyl; or R4 and R5 can be taken together to form -(CH2)rB(CH2)s- where B, r, s, R1 , R10 as defined above;
R6 is hydrogen, C1-C10 alkyl, phenyl or phenyl C1-C10 alkyl;
A is
where x and y are independently 0-3; R8 and R8a are independently hydrogen, C1-C10 alkyl, trifluoromethyl, phenyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, C3- C7 cycloalkyl, R1, R2 independently disubstituted phenyl C1-C3 alkoxy, R1, R2 independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, or -NR10R1 1 where R10 and R1 1 are as defined above; or R8 and R8a can be taken together to form -(CH2)t-where t is 2 to 6; and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof.
2. A compound of Claim 1 wherein: n is 0 or 1;
p is 0 to 4;
q is 0 to 2;
w is 0 or 1 ; R1 0
I
X is O, S(O)m, -N-, -CH=CH-;
m is 0 to 2; R1, R2, R1 a, R2a, R1b, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, -S(O)mR7a, R7bO(CH2)v-,
R7bCOO(CH2)v-, R7bOCO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; R7a and R7b are independently hydrogen, C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl; phenyl and v is 0 to 2;
R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9, or phenoxy substituted with R9;
R9 is as defined in Claim 1. R12a, R12b and R12c are independently R5a, OR5a or COR5a; R12a and R12b, or R12b and R12c, or R13 and R12b or R12a and R4b can be taken together to form -(CH2)r-B-(CH2)s- where B is CHR', O, S(O)m or NR10, m is 0, 1 or 2, r and s are independently 0 to 3, R1 is as defined above and R10 is hydrogen, C1-C6 alkyl, phenyl C1-C6 alkyl or C1-C5 alkanoyl -C1-C6 alkyl. R13 is C1-C3 perfluoroalkyl, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are hydroxy, NR10R1 1, carboxy, phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy or hydroxy; R14 and R15 are as defined in Claim 1; R4, R4a, R4b, R5 and R5a are independently hydrogen, phenyl, substituted phenyl, C1-C10 alkyl, substituted C1-C10 alkyl, where the substituents on the alkyl or phenyl are from 1 to 5 of hydroxy, Cl -C6 alkoxy, C3-C7 cycloalkyl, fluoro, R1 substituted or R1 , R2
independently disubstituted phenyl C1-C3 alkoxy, R1 substituted or R1, R2 independently disubstituted phenyl, C1-C20-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy or formyl; R4 and R5 can be taken together to form -(CH2)rB(CH2)s- where B is CHR1 , O, S(O)m or N-R10, r and s are independently 1 to 3 and R1 and R10 are as defined above;
R6 is hydrogen, C1-C10 alkyl or phenyl C1-C10 alkyl; A is
where x and y are independently 0-2; R8 and R8a are independently hydrogen, C1-C10 alkyl, substituted C1- C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, R1, R2 independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy, formyl, -NR10 R1 1 where R10 and R1 1 are independently hydrogen, C1-C6 alkyl, or C1-C5 alkanoyl-C1-C6 alkyl; or R8 and R8a can be taken together to form -(CH2)t- where t is 2 to 4; and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms; and pharmaceutically acceptable salts thereof.
3. A compound of Claim 2 wherein: n is 0 or 1;
p is 0 to 3;
q is 0 to 2;
w is 0 or 1;
X is O, S(O)m, -CH=CH-;
m is 0 or 1; R1, R2, R1 a, R2a, R1b, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, -S(O)mR7a, R7bO(CH2)v-,
R7bCOO(CH2)v-, R7bOCO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; R7a and R7b are independently hydrogen, C1-C6 alkyl, substituted C1- C6 alkyl, where the substituents are phenyl and v is 0 to 2;
R3a and R3b are independently hydrogen, R9, C1-C6 alkyl substituted with R9, phenyl substituted with R9 or phenoxy substituted with R9; R12a, R12b and R12c are independently R5a or OR5a. R12a and R12b, or R12b and R12c, or R13 and R12b or R12a and R4b can be taken together to form -(CH2)r-B-(CH2)s- where B is CHR1, O, S(O)m or NR10, m is 0, 1 or 2, r and s are independently 0 to 2, R1 is as defined above, and R10 is hydrogen, C1-C6 alkyl or C1-C5 alkanoyl-C1-C6 alkyl; R13 is C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1- C6 alkoxy or hydroxy; R4, R4a, R4b, R5 and R5a are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl, where the substituents on the alkyl are from 1 to 5 of hydroxy, C1-C6 alkoxy, fluoro, R1 substituted or R1, R2 independently disubstituted phenyl, C1-C20-alkanoyloxy, C1-C5 alkoxycarbonyl or carboxy;
R6 is hydrogen or C1-C10 alkyl; A is
where x and y are independently 0-2; R8 and R8a are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, R1 substituted or R1, R2 independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy; or R8 and R8a can be taken together to form -(CH2)t- where t is 2; or R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof.
4. A compound of Claim 3 wherein: n is 0 or 1;
p is 0 to 2;
q is 1 ;
w is 1;
X is O, S(O)m or -CH=CH-;
m is 0 or 1 ; R1, R2, R1 a, R2a, R1b, and R2b are independently hydrogen, halogen, C1-C7 alkyl, C1-C3 perfluoroalkyl, -S(O)mR7a, R7bO(CH2)v-,
R7bCOO(CH2)v-, phenyl or substituted phenyl where the substituents are from 1 to 3 of halogen, C1-C6 alkyl, C1 -C6 alkoxy, or hydroxy; R7a and R7b are independently hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl and v is 0 or 1;
R3a and R3b are independently hydrogen, R9, or C1-C6 alkyl substituted with R9; R12a, R12b and R12c are independently R5a. R12a and R12b, or R12b and R12c, or R13 and R12b or R12a and R4b can be taken together to form -(CH2)r-B-(CH2)s- where B is CHR1, O, S(O)m or NR10, m is 0, 1 or 2, r and s are independently 0 to 2, R1 is as defined above and R10 is hydrogen, C1-C6 alkyl or C1-C5 alkanoyl-C1-C6 alkyl; R13 is C1-C6 alkyl, substituted C1-C6 alkyl, where the substituents are phenyl or substituted phenyl; phenyl or substituted phenyl where the substituents on the phenyl are from 1 to 3 of halogen, C1-C6 alkyl, C1-C6 alkoxy or hydroxy; R4, R4a, R4b, R5, and R5a are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl, where the substituents on the alkyl are from 1 to 3 of hydroxy, C1-C3 alkoxy, fluoro, R1 substituted or R1, R2 independently disubstituted phenyl, C1-C20 alkanoyloxy, C1-C5 alkoxycarbonyl or carboxy;
R6 is hydrogen; A is
where x and y are independently 0-1; R8 and R8a are independently hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl where the substituents are from 1 to 3 of imidazolyl, indolyl, hydroxy, fluoro, S(O)mR7a, C1-C6 alkoxy, R1 substituted or R1, R2 independently disubstituted phenyl, C1-C5-alkanoyloxy, C1-C5 alkoxycarbonyl, carboxy; or R8 and R8a can be taken together to form -(CH2)t- where t is 2; and R8 and R8a can independently be joined to one or both of R4 and R5 to form alkylene bridges between the terminal nitrogen and the alkyl portion of the A group wherein the bridge contains from 1 to 5 carbon atoms;
and pharmaceutically acceptable salts thereof.
5. A stereospecific compound of Claim 1 having the following structural formula:
where X, n, p, q, L, w, R1 a, R2a, R3a, R4, R5, R6, R14, R15, and A are as defined in Claim 1 6. A compound of Claim 1 which is: (R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]benzenebutanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]benzenebutanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- benzenebutanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]benzenebutanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]benzenepentanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]benzenepentanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- benzenepentanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]benzenepentanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]-1H-indole-3- propanamide; (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1 ,1'-biphenyl]-4-yl]-methyl]-1H-indole-3- propanamide;
(R)-α -[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1 '-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1 '-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]-3-[(phenylmethyl)- oxy]propanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1 ,1' -biphenyl]-4-yl]-methyl]-3-[(phenylmethyl)- oxy]propanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)oxy]propanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)oxy]propanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-(1H-tetra- zol-5-yl)[1,1 '-biphenyl]-4-yl]-methyl]-3-[[(2,6-difluorophenyl)- methyl]oxy]propanamide; (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-(1H- tetrazol-5-yl)[1,1'-biphenyl]-4-yl]-methyl]-3-[[(2,6-difluoro- phenyl)methyl]oxy]propanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluorophenyl)methyl]oxy]propanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluorophenyl)-methyl]oxy]propanamide;
(R)-4'-[[[2-[(3-Amino-3-methyl-1-oxobutyl)amino]-1-oxo-4- phenylbutyl]amino]methyl]-N-ethyl[1,1'-biphenyl]-2-carboxa- mide;
(R)-4'-[[[2-[(2-Amino-2-methyl-1-oxopropyl)-amino]-1-oxo-4- phenylbutyl]amino]methyl]-N-ethyl[1,1'-biphenyl]-2-carboxa- mide;
(R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-1-oxo-4-phenylbutyl]-amino]methyl]-N-ethyl[1,1 '- biphenyl]-2-carboxamide;
(R)-4'-[[[2-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]amino]-1-oxo-4-phenylbutyl]-amino]methyl]-N-ethyl[1,1 '- biphenyl]-2-carboxamide;
(R)-4'-[[[2-[(3-Amino-3-methyl-1-oxobutyl)amino]-1-oxo-5- phenylpentyl]amino]methyl]-N-ethyl[1,1'-biphenyl]-2-carboxa- mide; (R)-4'-[[[2-[(2-Amino-2-methyl-1-oxopropyl)-amino]-1-oxo-5- phenylpentyl]amino]methyl]-N-ethyl[1,1'-biphenyl]-2-carboxa- mide;
(R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]amino]-1-oxo-5-phenylpentyl]-amino]methyl]-N-ethyl[1,1'- biphenyl]-2-carboxamide;
(R)-4'-[[[2-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-5-phenylpentyl]-amino]methyl]-N- ethyl[1,1'-biphenyl]-2-carboxamide;
(R)-4'-[[[2-[(3-Amino-3-methyl-1-oxobutyl)amino]-1-oxo-3-(1H- indole-3-yl)propyl]amino]methyl]-N-ethyl[1,1'-biphenyl]-2- carboxamide;
(R)-4'-[[[2-[(2-Amino-2-methyl-1-oxopropyl)-amino]-1-oxo-3-
(1H-indole-3-yl)propyl]amino]-methyl]-N-ethyl[1,1'-biphenyl]-2- carboxamide;
(R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-1-oxo-3-(1H-indole-3-yl)propyl]amino]methyl]-N- ethyl[1,1'-biphenyl]-2-carboxamide;
(R)-4'-[[[2-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-1-oxo-3-(1H-indole-3-yl)propyl]amino]methyl]-N- ethyl[1,1'-biphenyl]-2-carboxamide;
(R)-4'-[[[2-[(3-Amino-3-methyl-1-oxobutyl)amino]-1-oxo-3-
[(phenylmethyl)oxy]propyl]amino]methyl]-N-ethyl[1,1 '-biphenyl]-
2-carboxamide; (R)-4'-[[[2-[(2-Amino-2-methyl-1-oxopropyl)-amino]-1-oxo-3- [(phenylmethyl)oxy]propyl]amino]-methyl]-N-ethyl[1,1'- biphenyl]-2-carboxamide;
(R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-1-oxo-3-[(phenylmethyl)-oxy]propyl]amino]methyl]- N-ethyl[1,1'-biphenyl]-2-carboxamide;
(R)-4'-[[[2-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-3-[(phenylmethyl)-oxy]propyl]- amino]methyl]-N-ethyl[1 ,1'-biphenyl]-2-carboxamide;
(R)-4'-[[[2-[(3-Amino-3-methyl-1-oxobutyl)amino]-1-oxo-3- [[(2,6-difluorophenyl)methyl]oxy]propyl]-amino]methyl]-N- ethyl[1,1'-biphenyl]-2-carboxamide;
(R)-4'-[[[2-[(2-Amino-2-methyl-1-oxopropyl)-amino]-1-oxo-3- [[(2,6-difluorophenyl)methyl]oxy]-propyl]amino]methyl]-N- ethyl[1,1'-biphenyl]-2-carboxamide;
(R)-4'-[[[2-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-1-oxo-3-[[(2,6-difluoro-phenyl)methyl]oxy]- propyl]amino]methyl]-N-ethyl-[1,1'-biphenyl]-2-carboxamide;
(R)-4'-[[[2-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-1-oxo-3-[[(2,6-difluoro-phenyl)methyl]oxy]- propyl]amino]methyl]-N-ethyl-[1,1'-biphenyl]-2-carboxamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-[[(methylamino)carbonyl]amino][1,1 '-biphenyl]-4-yl]methyl]benzene- butanamide; (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-[[(methylamino)carbonyl]amino][1,1 '-biphenyl]-4-yl]methyl]benzenebutanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[(methylamino)carbonyl]-amino][1,1'-biphenyl]-4- yl]methyl]benzenebutanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxo- butyl]amino]-N-[[2'-[[(methylamino)carbonyl]-amino][1 ,1'- biphenyl]-4-yl]methyl]benzenebutanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-[[(methyl- amino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]benzenepentanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-[[(methylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]benzenepentanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]amino]-N-[[2'-[[(methylamino)carbonyl]-amino][1,1'- biphenyl]-4-yl]methyl]benzenepentanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[(methylamino)carbonyl]-amino][1,1'-biphenyl]-4- yl]methyl]benzenepentanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-[[(methylamino)carbonyl]amino][1 ,1'-biphenyl]-4-yl]methyl]-1H-indole-3- propanamide; (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-[[(methylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-1H-indole-3- propanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[(methylamino)carbonyl]-amino][1,1'-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[(methylamino)carbonyl]-amino][1,1'-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-[[(methylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]propanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-[[(methylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]propanamide;
(R)-a-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[(memylamino)carbonyl]-amino][1,1'-biphenyl]-4- yl]methyl]-3-[(phenyl-methyl)oxy]propanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[(methylamino)carbonyl]-amino][1,1'-biphenyl]-4- yl]methyl]-3-[(phenyl¬methyl)oxy]propanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-[[(methylamino)carbonyl]amino][1,1'-biphenyl]-4-yl]methyl]-3-[[(2,6- difluorophenyl)methyl]oxy]propanamide (R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-[[(methylamino)carbonyl]amino][1 ,1' -biphenyl]-4-yl]methyl]-3-[[(2,6- difluorophenyl)methyl]oxy]propanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[(methylamino)carbonyl]-amino][1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluorophenyl)methyl]oxy]propanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[(methylamino)carbonyl]-amino][1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluorophenyl)methyl]oxy]propanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-hydroxymethyl[1 ,1'-biphenyl]-4-yl]methyl]benzenebutanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]benzenebutanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]- benzenebutanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]- benzenebutanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]benzenepentanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]benzenepentanamide; (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]- benzenepentanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-hydroxymethyl[1,1'-biρhenyl]-4-yl]methyl]- benzenepentanamide;
(R)-α.-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-hydroxymethyl1l,1'-biphenyl]-4-yl]methyl]-1H-indole-3-propanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-1H-indole-3-propanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-1H- indole-3-propanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-1H- indole-3-propanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]- propanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]- propanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-3-
[(phenylmethyl)oxy]propanamide; (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1 - oxobutyl]amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)oxy]propanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-3-[[(2,6-difluorophenyl)- methyl]oxy]propanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'-hydroxymethyl[1 ,1' -biphenyl]-4-yl]methyl]-3-[[(2,6-difluorophenyl)- methyl]oxy]propanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-3- [[(2,6-difluorophenyl)methyl]oxy]propanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-hydroxymethyl[1,1'-biphenyl]-4-yl]methyl]-3- [[(2,6-difluorophenyl)methyl]oxy]propanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-[[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4-yl]methyl]- benzenebutanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]benzenebutanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[[(methylamino)carbonyl]-amino]methyl][1 ,1'- biphenyl]-4-yl]methyl]benzenebutanamide; (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[[(methylamino)carbonyl]-amino]methyl][1,1'- biphenyl]-4-yl]methyl]benzenebutanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-[[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4-yl]methyl]- benzenepentanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]benzenepentanamide; (R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1- oxobutyl]amino]-N-[[2'-[[[(methylamino)carbonyl]- amino]methyl][1,1'-biphenyl]-4-yl]methyl]benzenepentanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[[(methylamino)carbonyl]-amino]methyl][1,1'- biphenyl]-4-yl]methyl]benzenepentanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-[[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4-yl]methyl]-1H- indole-3-propanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]-1H-indole-3-propanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[[(methylamino)carbonyl]-amino]methyl][1 ,1'- biphenyl]-4-yl]methyl]-1H-indole-3-propanamide; (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[[(methylamino)carbonyl]-amino]methyl][1 ,1'- biphenyl]-4-yl]methyl]-1H-indole-3-propanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-[[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4-yl]methyl]-3-
[(phenylmethyl)-oxy]propanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[[(methylamino)carbonyl]ammo]methyl]-[1,1'-biphenyl]-4- yl]methyl]-3-[(phenylmethyl)-oxy]propanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[[(methylamino)carbonyl]-amino]methyl][1 ,1'- biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]propanamide;
(R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[[(methylamino)carbonyl]-amino]methyl][1 ,1'- biphenyl]-4-yl]methyl]-3-[(phenylmethyl)oxy]propanamide;
(R)-α-[(3-Amino-3-methyl-1-oxobutyl)amino]-N-[[2'-[[[(methylamino)carbonyl]amino]methyl][1,1'-biphenyl]-4-yl]methyl]-3- [[(2,6-difluorophenyl)-methyl]oxy]propanamide;
(R)-α-[(2-Amino-2-methyl-1-oxopropyl)amino]-N-[[2'- [[[(methylamino)carbonyl]amino]methyl]-[1,1'-biphenyl]-4- yl]methyl]-3-[[(2,6-difluoro-phenyl)methyl]oxy]propanamide;
(R)-α-[[3-[2(R)-Hydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[[(methylamino)carbonyl]-amino]methyl][1 ,1'- biphenyl]-4-yl]methyl]-3-[[(2,6-difluorophenyl)methyl]oxy]- propanamide; or (R)-α-[[3-[2(S),3-Dihydroxypropyl]amino-3-methyl-1-oxobutyl]- amino]-N-[[2'-[[[(methylamino)carbonyl]-amino]methyl][1 ,1'- biphenyl]-4-yl]methyl]-3-[[(2,
6-difluorophenyl)methyl]oxy]- propanamide.
7. A process for the preparation of a compound of Claim 1 which comprises reacting a compound having a formula:
where R6, R15, X, n and p are as defined in Claim 1 with a compound having the formula:
where R4 and A are defined in Claim 1 and G is a protecting group; which step is either followed by or preceded by the treatment of the compound with
where R1 a, R2a, R3a, R14, L, q and w are as defined in Claim 1, followed by replacement of the protecting group G with R5.
8. The process of Claim 7 where compound II is first reacted with compound III followed by reaction with compound V.
9. A process for the preparation of a compound of Claim 1 which comprises reacting a compound having a formula:
where R4, R6, R15, A, X, n and p are as defined in Claim 1 and G is a protecting group, with a compound having the formula: '
where R1 a, R2a, R3a, R14, L, q and w are as defined in Claim 1 , followed by replacement of the protecting group G with R5.
10. The process of Claim 9 where the protecting group G is t-butoxycarbonyl or benzyloxycarbonyl.
1 1. A method for increasing levels of endogenous growth hormone in a human or an animal which comprises
administering to such human or animal an effective amount of a compound of Claim 1.
12. A composition useful for increasing the endogenous production or release of growth hormone in a human or an animal which comprises an inert carrier and an effective amount of a
compound of Claim 1.
13. A composition useful for increasing the endogenous production or release of growth hormone in a human or an animal which comprises an inert carrier and an effective amount of a
compound of Claim I used in combination with other growth hormone secretagogues such as, GHRP-6 or GHRP-1, growth hormone releasing factor (GRF) or one of its analogs, IGF-1 or IGF-2, or B-HT920.
14. A method for the treatment of obesity which comprises administering to an obese patient an effective amount of a compound of Claim 1 in combination with an α2-adrenergic agonist or β3-adrenergic agonist.
15. A composition for the treatment of obesity which comprises an inert carrier and an effective amount of a compound of Claim 1 in combination with an α2-adrenergic agonist or β3-adrenergic agonist.
16. A method for the treatment of osteoporosis which comprises administering to a patient with osteoporosis an effective amount of a compound of Claim 1 in combination with parathyroid hormone or a bisphosphonate.
17. A composition for the treatment of osteoporosis which comprises an inert carrier and an effective amount of a
compound of Claim 1 in combination with parathyroid hormone or a bisphosphonate.
AU55469/94A 1992-11-06 1993-10-29 Substituted dipeptide analogs promote release of growth hormone Ceased AU676525B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97314292A 1992-11-06 1992-11-06
PCT/US1993/010551 WO1994011012A1 (en) 1992-11-06 1993-10-29 Substituted dipeptide analogs promote release of growth hormone
US973142 2001-10-09

Publications (2)

Publication Number Publication Date
AU5546994A AU5546994A (en) 1994-06-08
AU676525B2 true AU676525B2 (en) 1997-03-13

Family

ID=25520551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55469/94A Ceased AU676525B2 (en) 1992-11-06 1993-10-29 Substituted dipeptide analogs promote release of growth hormone

Country Status (5)

Country Link
EP (1) EP0669830A4 (en)
JP (1) JPH08503213A (en)
AU (1) AU676525B2 (en)
CA (1) CA2147503A1 (en)
WO (1) WO1994011012A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09505601A (en) * 1993-11-24 1997-06-03 メルク エンド カンパニー インコーポレーテッド Indolyl-containing compounds and their use to promote growth hormone release
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
WO1996038471A1 (en) * 1995-05-29 1996-12-05 Pfizer Inc. Dipeptides which promote release of growth hormone
JPH08325248A (en) * 1995-05-26 1996-12-10 Chugoku Kayaku Kk New reagent for synthesizing tetrazole compound and production of tetrazole compound using the same
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
ATE334394T1 (en) 1995-12-13 2006-08-15 Merck & Co Inc TEST METHODS FOR THE SECRETION RECEPTORS OF GROWTH HORMONES
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
USRE38524E1 (en) 1997-06-25 2004-06-01 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (en) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Treatment of insulin tolerance using substances increasing growth hormone secretion
UA53716C2 (en) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. A substituted dipeptide tartaric salt as an agent stimulating the growth hormone secretion
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
JP2002520011A (en) 1998-07-13 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド Growth hormone secretagogue-related receptors and nucleic acids
US6645726B1 (en) 1998-08-10 2003-11-11 Merck & Co., Inc. Canine growth hormone secretagogue receptor
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
EP1158996A4 (en) 1999-02-18 2005-01-12 Kaken Pharma Co Ltd Novel amide derivatives as growth hormone secretagogues
ATE446758T1 (en) 2000-05-31 2009-11-15 Pfizer Prod Inc USE OF GROWTH HORMONE SECRETAGOGENES TO PROMOTE DIGESTIVE MOTILITY
EP2189457A1 (en) 2003-01-16 2010-05-26 Teva Pharmaceutical Industries Ltd. Novel synthesis of irbesartan
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
ES2302671T1 (en) * 2006-08-29 2008-08-01 Teva Pharmaceutical Industries Ltd. PROCEDURES FOR THE SYNTHESIS OF 5-PHENYL-1-TRITIL-1H-TETRAZOL.
AU2008241532A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
US20100099640A1 (en) 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
MX2016015467A (en) 2014-05-30 2017-03-23 Pfizer Carbonitrile derivatives as selective androgen receptor modulators.
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN106748860A (en) * 2016-11-22 2017-05-31 浙江工业大学 Method for ortho-arylating specific functional group on benzene ring by palladium/carbon catalysis
EP3732165B1 (en) * 2017-12-27 2022-08-17 Flamma S.P.A. Peptide derivatives and therapeutic activity thereof
US20230122967A1 (en) * 2020-01-17 2023-04-20 Shengke Pharmaceuticals (Jiangsu) Ltd. Novel compounds as inhibitors of pcsk9
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5132793A (en) * 1992-09-30 1994-04-26 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
AU5132293A (en) * 1992-09-25 1994-04-26 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE122357T1 (en) * 1988-01-28 1995-05-15 Polygen Holding Corp POLYPEPTIDES WITH A HORMONE-GROWTH-LIBERATING EFFECT.
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5132293A (en) * 1992-09-25 1994-04-26 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
AU5132793A (en) * 1992-09-30 1994-04-26 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Also Published As

Publication number Publication date
AU5546994A (en) 1994-06-08
EP0669830A4 (en) 1997-02-26
CA2147503A1 (en) 1994-05-26
JPH08503213A (en) 1996-04-09
WO1994011012A1 (en) 1994-05-26
EP0669830A1 (en) 1995-09-06

Similar Documents

Publication Publication Date Title
AU676525B2 (en) Substituted dipeptide analogs promote release of growth hormone
AU676501B2 (en) Benzo-fused lactams promote release of growth hormone
EP0659179B1 (en) Benzo-fused lactams promote release of growth hormone
US5606054A (en) Heterocyclic-fused lactams promote release of growth hormone
US5206235A (en) Benzo-fused lactams that promote the release of growth hormone
WO1995009633A1 (en) Benzo-fused lactams promote release of growth hormone
US5374721A (en) Benzo-fused lactams promote release of growth hormone
WO1995003290A1 (en) Benzo-fused lactams promote release of growth hormone
US5583130A (en) Benzo-fused lactams promote release of growth hormone
WO1995003289A1 (en) Benzo-fused lactams promote release of growth hormone
US5438136A (en) Benzo-fused macrocycles promote release of growth hormone
US5726319A (en) Biphenyl substituted dipeptide analogs promote release of growth hormone
WO1995016675A1 (en) Benzo-fused lactams promote release of growth hormone
JP2002528417A (en) Benzoazepine compounds and their derivatives useful as growth hormone secretagogues

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired